Artificial metallonucleases - molecular tools for gene therapy of cancer by HASH(0x7fe99054bdb8)
 
 
 
 
 
 
 
Ph.D. dissertation 
 
ARTIFICIAL METALLONUCLEASES - MOLECULAR 
TOOLS FOR GENE THERAPY OF CANCER 
 
HEBA ALAA ELDEEN HOSINY ABD ELHAMEED 
 
 
Supervisor: 
DR. BÉLA GYURCSIK 
Associate professor 
 
 
 
 
 
 
Doctoral School of Chemistry 
 
Department of Inorganic and 
Analytical Chemistry 
 
Faculty of Science and Informatics 
 
University of Szeged, Hungary 
 
                      2020 
 
 
 
  
 
 
 
Table of Contents 
List of Abbreviations ................................................................................................................................ 1 
1. INTRODUCTION ................................................................................................................................... 2 
2. LITERATURE REVIEW ........................................................................................................................... 3 
2.1. Cancer ........................................................................................................................................... 3 
2.2. Genome editing ............................................................................................................................ 5 
2.2.1. Definition and the mechanism of genome editing ............................................................... 5 
2.3. Artificial nucleases ........................................................................................................................ 6 
2.3.1. Zinc finger nucleases (ZFNs) .................................................................................................. 7 
2.3.2. Transcription activator like effector nucleases (TALENs) ...................................................... 9 
2.3.3. CRISPR/Cas RNA-guided nucleases ..................................................................................... 11 
2.3.4. The NColE7 nuclease domain (structure, function, consequences of mutations and 
regulation) ..................................................................................................................................... 13 
2.3.5. NColE7-based integrated zinc finger nucleases .................................................................. 15 
2.4. The delivery of programmable nucleases .................................................................................. 16 
2.4.1. Non-viral delivery methods ................................................................................................. 17 
2.4.1.1. Physical delivery methods ................................................................................................ 17 
2.4.1.2. Chemical delivery methods .............................................................................................. 18 
2.4.2. Viral delivery methods ........................................................................................................ 21 
3. AIMS AND OBJECTIVES ...................................................................................................................... 23 
4. METHODS .......................................................................................................................................... 26 
4.1. Recombinant protein production ............................................................................................... 26 
4.1.1. Recombinant DNA technology ............................................................................................ 26 
4.1.2. Protein expression and purification .................................................................................... 29 
4.1.2.1. Immobilized metal affinity chromatography (IMAC) ....................................................... 30 
4.1.2.2. Cation exchange chromatography ................................................................................... 30 
4.2. Characterization of proteins....................................................................................................... 31 
4.2.1. SDS-PAGE ............................................................................................................................. 31 
4.2.2. Mass spectrometry of metalloproteins ............................................................................... 31 
4.2.3. Study of protein solution structure by circular dichroism spectroscopy ............................ 34 
4.2.4. Determination of protein concentration ............................................................................ 35 
4.3. Catalytic activity assays .............................................................................................................. 36 
4.3.1. Agarose gel electrophoresis ................................................................................................ 36 
 
 
4.4. Synthesis and characterization of the water-soluble lipopolymer ............................................ 37 
4.4.1. Synthesis and purification of the water-soluble lipopolymer ............................................. 37 
4.4.2. Particle charge detection .................................................................................................... 38 
4.5. Characterization of WSLP/pDNA complexes .............................................................................. 38 
4.5.1. Dynamic light scattering ...................................................................................................... 38 
4.5.2. Electron microscopy ............................................................................................................ 39 
4.6. Experiments with cancer cell lines ............................................................................................. 40 
4.6.1. Cell culture materials .......................................................................................................... 40 
4.6.2. MTT assay ............................................................................................................................ 41 
4.6.3. Internalization of plasmid DNA into the cancer cells .......................................................... 42 
4.6.4. Fluorescence microscopy .................................................................................................... 42 
5. RESULTS AND DISCUSSION ................................................................................................................ 44 
5.1 Design of a new DNA construct for affinity based purification of ΔN4-NColE7 .......................... 44 
5.1.1. Construction of the new cloning site into the pET-21a (AmpR) DNA vector ....................... 44 
5.1.2 Expression and purification of ΔN4-NColE7-6×His by nickel-affinity resin .......................... 47 
5.2 Modulation of the catalytic activity of NColE7 by the 6×His tag ................................................ 50 
5.2.1. DNA cloning and cytotoxicity experiments reflecting the catalytic activity of the nucleases
 ....................................................................................................................................................... 50 
5.2.2. Purification and characterization of KGNK-6×His protein ................................................... 55 
5.2.3. DNA cleavage experiments with the KGNK-6×His protein .................................................. 56 
5.2.4. Mass spectrometric analysis of the metal ion binding properties of the KGNK-6×His ....... 59 
5.2.5. Influence of the His tag on the structural integrity of KGNK-6×His .................................... 62 
5.3 DNA targeting by artificial nucleases .......................................................................................... 64 
5.3.1. Construction and optimization of CRISPR/Cas9 system for targeting the epidermal growth 
factor receptor (EGFR, ErbB1) oncogene ...................................................................................... 64 
5.3.2. Screening of CRISPR/Cas9 system on mammalian cell culture ........................................... 67 
5.3.2.1.Transfection of the cancer cells ........................................................................................ 67 
5.3.2.2. Genomic DNA extraction and sequencing ....................................................................... 67 
5.3.2.3. RNA extraction and qRT-PCR analysis .............................................................................. 69 
5.4. Delivery of the artificial nucleases into the mammalian cells .................................................... 71 
5.4.1. Synthesis and characterization of water-soluble lipopolymer ............................................ 71 
5.4.1.1. Particle charge detection ................................................................................................. 72 
5.4.2. pDNA condensation efficiency of the water-soluble lipopolymer ...................................... 74 
5.4.3. Characterization of WSLP/DNA complexes ......................................................................... 76 
5.4.4. Cytotoxicity assay ................................................................................................................ 78 
 
 
5.4.5. In vitro transfection ............................................................................................................. 79 
5.4.6. Assessment of WSLP/pX458 complexes activity by in vitro gene knockout assay ............. 81 
5.5. Development of specific and regulated NColE7-based zinc finger artificial nuclease ............... 82 
5.5.1. Design of new zinc finger nuclease variants ....................................................................... 82 
5.5.2. Proteins used in this work ................................................................................................... 84 
5.5.3. Expression and purification of the designed proteins ........................................................ 87 
5.5.4. Plasmid cleavage activity of the C45-ZF-N85 artificial nuclease ......................................... 89 
5.5.5. Double strand cleavage in short oligonucleotides .............................................................. 93 
5.5.6. Mutation of the C45-ZF-N85 and C45-ZF nucleases for targeting ErbB1(EGFR) oncogene 94 
6. SUMMARY AND FUTURE OUTLOOK .................................................................................................. 96 
7. REFERENCES ...................................................................................................................................... 99 
8. ACKNOWLEDGEMENTS ................................................................................................................... 108 
9. PUBLICATION LIST ........................................................................................................................... 109 
10. APPENDIX ...................................................................................................................................... 112 
 
 
 
 
  
 
 
 
1 
 
List of Abbreviations 
A549 human lung cancer cells 
AAV adeno-associated virus 
AN artificial nuclease 
BL21(DE3), DH5, 
Mach1 
E. coli strains 
Cas9 CRISPR-associated nuclease 9 
CD circular dichroism 
CPP cell-penetrating peptide 
CRISPR clustered regularly interspaced short palindromic repeats 
crRNA changeable CRISPR RNA 
DLS dynamic light scattering 
DMEM Dulbecco’s modified eagle medium 
DSB double-strand break 
E. coli Escherichia coli 
EGFR epidermal growth factor receptor 
ESI electrospray ionization 
BbsI, BsmBI, FokI, 
VspI  
restriction endonucleases 
FPLC fast protein liquid chromatography 
gRNA guide RNA 
HDR homology-directed repair 
IMAC immobilized metal affinity chromatography 
IPTG isopropyl β-D-1-thiogalactopyranoside 
KGNK R447G mutant of the NColE7 protein 
LB lysogeny broth or commonly Luria-Bertani medium 
LV Lentivirus 
MALDI matrix-assisted laser desorption/ionization 
MS mass spectrometry 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
NColE7 nuclease domain of the Colicin E7 
NHEJ non-homologous end-joining 
NMR nuclear magnetic resonance spectroscopy 
NTA nitrilotriacetic acid 
OD optical density 
PAM protospacer adjacent motif 
PCD particle charge detector 
PCR polymerase chain reaction 
pEGFP-N3, pET-21a, 
pX458 
name of DNA plasmid 
PEI poly(ethylenimine) 
RNP Ribonucleoprotein 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM scanning electron microscope 
SRCD synchrotron radiation circular dichroism 
dsDNA, ssDNA double-strand and single strand DNA, respectively 
TALEN transcription activator-like effector nuclease 
TCEP tris(2-carboxyethyl)phosphine) 
TEM transmission electron microscopy 
tracrRNA trans-activating crRNA 
WSLP water-soluble lipopolymer 
ZFN zinc finger nuclease 
ZFP zinc finger protein 
ΔN4-NColE7 nuclease domain of Colicin E7 lacking the four N-terminal amino acids 
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1. INTRODUCTION 
 
All cancer cells contain multiple genetic mutations that allow them to grow progressively 
and exhibit the characteristics of malignancy. Therefore, targeting the cancer cell genome is an 
attractive approach of cancer therapy. The ability to redeem such cancer-associated mutations 
requires a reagent which should induce correction of genetic changes in a highly specific 
manner without off-target effects. The reagent would also require efficient delivery into all or 
nearly all cells of a tumor. In the last decades, novel genetic-editing technologies have been 
developed, based on artificial nucleases (ANs). These ANs have important potential clinical 
applications including the treatment of genetic diseases, viral infections, and cancer. These new 
classes of reagents, which can specifically target nucleotide sequences within cellular genomes, 
are of four major types: meganucleases, zinc-finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and the clustered regulatory interspaced short palindromic 
repeat (CRISPR) and its associated nuclease 9 (Cas9) system. However, all of the above 
artificial nucleases have various levels of cytotoxicity.  
Therefore, the goal of our research group is to develop a regulated zinc finger nuclease, 
which is based on Colicin E7 metallonuclease domain (NColE7) instead of the widely used 
FokI nuclease domain in the ZFNs and TALENs. Accordingly, new ANs should be developed, 
in which the various parts of the enzyme regulate the catalytic activity so that the DNA 
hydrolysis only occurs when the enzyme binds to its specific target site. In addition, any damage 
of the enzyme should cancel its function, rather than lead to non-specific cleavages. 
On this path, the development of such an AN includes various approaches presented in 
this thesis. (i) The optimization of NColE7 based AN depends largely on understanding of the 
intramolecular regulation of the NColE7 nuclease within the native and modified variants, 
including the zinc finger – NColE7 ANs. (ii) The design of CRISPR/Cas9 ANs to target and 
knockout selected oncogenes promotes the selection of the most efficient DNA recognition sites 
for the new types of ANs. It also allows for comparison of different types of ANs. (iii) The 
optimization of gene delivery systems using high molecular weights poly(ethylenimine) (PEI) 
modified into a water-soluble lipopolymer (WSLP) increases the bioavailability and efficiency 
of the ANs. 
The results of my PhD work are intended to contribute to the development of an artificial 
metallonulease with improved specificity and effectivity for potential gene therapy. 
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2. LITERATURE REVIEW 
2.1. Cancer  
Cancer threats the human persistently and is evaluated to cause one in seventh deaths 
over the world [1]. This illness is defined as the alteration of normal and healthy tissue into 
malignant and interfering tissue, which intensely divides and consumes the requirements of 
other cells [2]. Various mutations leading to cancer might be initiated by environmental factors 
like radiation or chemicals during the DNA replication in the normal cells [3], while 
approximately fifth of all the human cancers is related to viral infections [4,5]. Cancerous 
mutations can be classified into several groups according to gene function as (i) overexpressed 
oncogenes, (ii) nonfunctional tumor suppressors, (iii) modification of epigenetic controls and 
(iv) or genes that confer chemoresistance. 
(i) Oncogenes: Proto-oncogenes are a group of genes that cause normal cells to become 
cancerous when they are mutated. The mutated version of a proto-oncogene is called an 
oncogene. Proto-oncogenes encode proteins that function to stimulate cell division, inhibit cell 
differentiation, and prevent cell death. Cancer cells typically exhibit increased production of 
these proteins, thus leading to the cell grows out of control. (Figure 2.1). Proto-oncogenes are 
e.g., the genes of the erythroblastic oncogene B (ErbB) family receptor tyrosine kinase 
enzymes. These proteins are structurally related to the epidermal growth factor receptor 
(EGFR). In humans, the ErbB family includes ErbB1 (EGFR), ErbB2, ErbB3 and ErbB4 [6]. 
As the consequence of gene mutation, these proteins are overexpressed mainly in breast cancer. 
SRC is a proto-oncogene coding for sarcoma (src) non receptor tyrosine kinase, which is 
mutated in numerous types of cancers of the colon, liver, lung, breast and the pancreas [7]. 
Additional types of oncogenes include the genes of the G-protein family (e.g. Rat Sarcoma; 
Ras), which are present in 20-30% of all human cancers [8] and intracellular protein kinases 
(e.g. Rapidly Accelerated Fibrosarcoma; Raf), with 20% of all human tumors displaying a 
mutated B-Raf gene mostly in renal cell carcinoma and melanoma [9]. Oncogenic nuclear 
transcription factors (e.g. myc, which is originally isolated from an avian myelocytomatosis 
virus) are amplified in epithelial ovarian, breast, gastric, pancreatic, colorectal and uterine 
cancers [10].  
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Figure 2.1. Illustration of how a normal cell is converted to a cancer cell when an oncogene 
becomes activated. This image was released by the National Cancer Institute, an agency part of 
the National Institutes of Health, with the ID 2351. 
 
(ii) Tumors suppressors stop the cell division or initiate the apoptosis. The p53 tumor 
suppressor protein is the most known one mutated in about fifty percent of human cancers [11]. 
Breast cancer-1 (BRCA1) [12] and breast cancer-2 (BRCA2) proteins also represent tumor 
suppressors in breast and ovarian cancers, respectively. The ataxia-telangiectasia (ATM) tumor 
suppressor is mutated in some types of leukemias and lymphomas. 
(iii) Epigenetic factors which regulate the gene expression are downregulated in cancer cells. 
Examples are DNA methyltransferases (DNMTs) and enzymes responsible for histone 
modifications, e.g., lysine-specific demethylase 1 (LSD1), enhancer of zeste homolog 2 
(EZH2), and nuclear receptor binding SET domain protein 2 (NSD2) [13]. 
(iv) Chemoresistance genes: The ability of cancer cells to develop chemoresistance towards 
drugs is a major obstacle in many cancer therapies. Overexpression of e.g., ABC transporters 
leads to increased drug resistance. An example is the multi-drug resistance 1 (MDR1) gene, 
from which the P-glycoprotein is expressed [14]. Another efflux protein is the multidrug 
resistance-associated protein 2 (MRP2) [15]. There are enzymes that activate or deactivate the 
chemotherapies and decrease the amount of the drug available to target the cancerous cells, 
such as the glutathione-S-transferase (GST) enzyme, which inactivates cisplatin [16]. Another 
example is the superfamily of the cytochrome P450 monooxygenase heme enzymes 
metabolizing various drugs [17].  
 The aim of cancer treatment is to get rid of the cancer cells while keeping the normal 
cells unaffected. Surgery includes the removal of the solid tumors but it is ineffective towards 
the small and metastatic tumors [18]. The current therapeutic methods are based on 
chemotherapy or radiation therapy. Chemotherapy utilizes chemical drugs to disrupt the DNA 
replication to kill the rapidly multiplying cells. Oncogenic proteins are also major molecular 
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targets for anti-cancer drug design. However, these treatments have cytotoxic side effects 
because most of them target both normal and cancer cells [19].  
 Nowadays, gene therapy is a potentially effective and challenging therapeutic tool 
because all cancers have genetic mutations roots. Cancer gene therapy permits selective 
targeting and repair of cancer cells only. Gene therapy tools are still under progress, aiming at 
e.g., introducing tumor suppressor genes or knocking out oncogenes in the cancerous cells [20]. 
 
2.2. Genome editing 
2.2.1. Definition and the mechanism of genome editing 
In the last decades, genome editing as a novel technology has attracted much attention 
of the researchers and enabled to manipulate any gene sequence in plant, animal and human 
cells. A successful approach is based on artificial nucleases, which consist of a sequence-
specific DNA binding domain cooperating with a non-specific DNA cleavage unit [21]. These 
ANs promise a potential to treat various human genetic diseases, such as e.g. haemophilia, 
sickle-cell anemia and several types of cancer. The therapeutic influence of genome editing is 
obtained by modifying accurately targeted specific DNA sequence inside cells by insertion, 
deletion, disruption, mutation, or replacement [22,23]. The first important step of genome 
editing is the double-strand break (DSB) at the DNA sequence of interest. This DSB is 
recognized in the cell and can be repaired by two pathways: non-homologous end-joining 
(NHEJ) or homology-directed repair (HDR) (Figure 2.2).  
 
Figure 2.2. Genome editing is initiated by engineered nucleases through double-strand DNA 
breaks (DSBs) at specific site within the genome. These DSBs can be repaired by two pathways: 
non-homologous end-joining (NHEJ) left or homology-directed repair (HDR) right [24]. 
 
NHEJ results in small, random insertions / deletions (indels) at the cleavage site, which 
often leads to a non-functional protein product if the indels cause a reading frame shift within 
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the gene of the expressed protein. HDR catalyzes the DNA repair at the cleaved site by using a 
DNA template of intact sequence for the precise correction of the DNA. HDR repair mechanism 
is less effective than NHEJ [25]. 
 
2.3. Artificial nucleases 
Programmable nucleases such as meganucleases, zinc finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced 
short palindromic repeats (CRISPR) /CRISPR-associated nuclease 9 (Cas9) or often also called 
RNA-guided engineered nucleases (RGENs) are now widely used for genome editing in various 
cells, and possess a broad range of novel applications in biotechnology and medicine [26]. 
These engineered nucleases are ‘molecular scissors’ causing breaks in the DNA. ANs are 
categorized according to their mode of action to target a specific DNA sequence (Figure 2.3).  
 
Figure 2.3. Schematic illustration of the four types of artificial nucleases. (A) The DNA 
cleavage domain of the I-SceI meganuclease is shown in red. (B) A ZFN dimer is represented 
in complex with the DNA. The two zinc fingers (blue) bind to the specific DNA target, while 
the nuclease domain of FokI (NFokI) (red) is the catalytic domain which dimerizes at the 5–7 
bp spacer and cleaves the DNA within it. (C) A TALEN consists of NFokI as nuclease domain 
(red) and the DNA binding domains, shown in blue. The recognition sites are separated by a 
15–20 bp spacer. (D) The CRISPR/Cas9 system binds to its specific DNA target by the help of 
the guide RNA (gRNA) through base pairing. The cleavage by Cas9 is represented by red 
arrowheads [27]. 
 
Meganucleases, ZFNs and TALENs use DNA-protein interactions in targeting specific 
DNA sequence for DNA cleavage, while CRISPR-Cas9 is directed by DNA-RNA interactions 
to bind the target gene. The DNA recognition of meganucleases is difficult to redesign. In the 
following, I will only discuss ZFNs, TALENs and RGENs. 
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2.3.1. Zinc finger nucleases (ZFNs) 
Zinc finger NFokI nucleases represent the first generation of the modular enzymes for 
genome editing. They have been utilized to target and change specific gene sequences in 
numerous organisms such as bacteria, viruses, plants, insects, fish and mammals such as mice 
and pigs, as well as in cultured mammalian cells [28,29]. In humans, the C-C motif chemokine 
receptor 5 (CCR5) gene was one of the first ZFN targets. The product of this gene is a co-
receptor for human immunodeficiency virus 1 (HIV-1) responsible for inducing acquired 
immunodeficiency syndrome (AIDS). ZFNs have been designed to target this gene in the T-
cells isolated from HIV patients. The patients were injected with the gene edited cells. Hopeful 
initial results revealed increased T-cell levels, indicating that the virus was not able to destroy 
these cells[30]. 
 
Figure 2.4. Structure of ZFNs. a, Schematic illustration of a zinc finger nuclease (ZFN) pair 
bound to specific DNA recognition sequence. Each ZFN is composed of a zinc-finger protein 
(ZFP) at the N-terminus and NFokI at C-terminus. In the consensus zinc-finger motif, X 
represents any amino acid. Target sequences of ZFN pairs are usually 18–36 bp in length. b, 
Model of ZFN pairs bound to DNA is shown. Zinc fingers are shown by pink ribbons (left) or 
by space-filling (right) representation. The grey region is the peptide linker between the DNA-
binding and catalytic domains. The NFokI cleavage domains are shown in blue and purple using 
space-filling representations. DNA is represented as the sugar-phosphate backbone in orange 
and the bases in blue. The separation between ZF binding sites is 6 bp [31]. 
 
These artificial programmable nucleases are created by fusing an N-terminal zinc finger 
protein (ZFP) as a DNA binding domain to a C-terminal DNA cleavage domain of FokI 
restriction enzyme (NFokI) [32] (Figure 2.4). Zinc finger domains can be engineered to target 
Consensus zinc-finger motifa
b
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the desired specific DNA sequences, and this enables zinc-finger nucleases to target unique 
sequences within complex genomes. 
ZFPs are composed of arrays of Cys2His2 (C2H2) zinc-fingers which are the most 
common types of DNA binding domains in the eukaryotes. Each zinc finger has about 30 amino 
acids, forming one α helix and two short β strands in the presence of the Zn2+ ion. Each finger 
binds to three adjacent nucleotides by the specific protein side chains within the major groove 
of DNA. The initial contacts are established by residues –1,3 and 6 related to the beginning of 
the α helix as shown in Figure 2.5. The DNA specificity of the zinc finger can be changed 
almost arbitrarily by varying the interacting amino acids. 3–6 zinc finger arrays are used to 
generate a ZFN subunit that binds to DNA sequences of 9–18 bp. A 18 base pair long DNA 
recognition sequence could increase the specificity even within the 68 billion bp of DNA being 
much larger than the human genome. The designed three or four finger ZFNs had successful 
applications. Increasing the number of the fingers increases the specificity but unfortunately 
decreases the possibility of finding a proper target site within the genome [33,21].  
 
 
Figure 2.5. The Cys2His2 zinc finger motif and the amino acid sequences of finger motifs in 
Zif268 ZFP. (Top) A ribbon diagram of finger 2 from Zif268 including the two cysteine side 
chains (yellow) and two histidine side chains (red) that coordinate the zinc ion (silver sphere). 
The side chains of key residues at positions that make base contacts in the major groove of the 
DNA are indicated by the numbers identifying their position relative to the start of the 
recognition helix. (Bottom) The amino acid sequence alignment of the three fingers from Zif268 
shows the conserved cysteines and histidines in boldface. Secondary structure elements are 
indicated at the bottom of the diagram [34]. 
 
The crystal structures of a ZFPs in their complexes with DNA indicated that zinc finger–
DNA interactions are modular in nature; each zinc finger contacts almost individually with a 
triplet DNA sequence (PDB IDs: 1MEY, 2I13 and 1ZAA). Definitely, new ZFPs with preferred 
specificities can be modularly assembled from pre-distinguished zinc-finger units [35]. Zinc 
fingers prepared by this method are usually not strictly specific in their DNA targeting [36,37]. 
It still challenging to design ZFNs with high activity, specificity and low cytotoxicity using 
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widely available resources. Various computer programs are available for finding the possible 
ZFN target sites in any DNA sequence (Table 2.1). 
 
Table 2.1. Resources for programmable nuclease design [31] 
 
 Online resources for nuclease design Non-profit 
organization 
Company 
ZFNs • Genome-wide tag scanner for nuclease 
off-sites 
• The Segal Laboratory software site 
• ZFN target site algorithm for 
identifying sites compatible with the 
Lawson-Wolfe modular assembly 
system 
• Zinc-finger tools 
• ZiFiT Targeter software 
• Addgene • Sigma-Aldrich 
• ToolGen 
TALENs • E-TALEN 
• Genome engineering resources 
• Scoring algorithm for predicting 
TALE(N) activity 
• ToolGen TALEN Designer 
• ZiFiT Targeter software 
• Addgene 
• TALEN 
library 
resource 
• Cellectis Bioresearch 
• Life Technologies 
• ToolGen 
• Transposagen 
• Biopharmaceuticals 
RGENs • E-CRISP 
• Genome engineering resources 
• RGEN tools 
• ZiFiT Targeter software 
• Addgene • Life Technologies 
• Sigma-Aldrich 
• System Biosciences 
• ToolGen 
• Transposagen 
• Biopharmaceuticals 
 
NFokI domains dimerize on the DNA and produce a double-strand break (DSB) with 
5’overhangs [38]. Therefore, an active nuclease requires two A and B ZFN monomers. Each 
monomer must bind to its adjacent half-site. This binding mode duplicates the length of the 
recognized DNA site, which significantly increases ZFNs specificity. Nevertheless, both ZFNs 
can also form homodimers to cleave DNA when only A or B ZFNs bind to DNA causing 
undesirable off-target effects. The NFokI dimeric interface was genetically modified to allow 
only heterodimers [39,40], which greatly decreased the off-target effects of ZFNs in a test 
system. FokI domains with improved action were also produced by directed evolution. 
 
2.3.2. Transcription activator like effector nucleases (TALENs) 
Recently, TALEs as programmable DNA binding proteins were discovered [41,42]. 
TALEs are natural proteins derived from Xanthomonas spp plant pathogenic bacteria. TALEs 
penetrate the nucleus of the host cell, alter the gene to promote the bacterial infection [43]. 
TALEs structure is similar to that of ZFs but in contrast to zinc fingers, TALE repeat bind DNA 
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forward, in other words, the N-terminal repeat binds the 5’ base pair. A TALE protein is a 
tandem array of 33–35 amino acid repeat units. Each TALE repeat identifies a single 
deoxynucleotide in the major groove of the DNA [44]. The two amino acids at positions 12 and 
13 determine the base pair specificity of a single repeat unit (Figure 2.6). These two amino 
acids are termed repeat variable diresidues (RVDs) [45]. Four different RVDs, namely Asn-
Asn (NN), Asn-Ile (NI), His-Asp (HD) and Asn-Gly (NG) are most commonly used to 
recognize G, A, C, T deoxynucleotides, correspondingly. Only residue 13 binds DNA, while 
the side-chain of residue 12 folds back and stabilizes the contacts with other residues in the 
TALE protein module. 
 
 
 
Figure 2.6. Structure of TALENs. a, Schematic representation of a TALEN pair. Each 
TALEN consists of transcription activator-like effectors (TALEs) at N-terminus and the NFokI 
nuclease domain at C-terminus. Each TALE repeat is composed of 33–35 amino acids and 
recognizes a single base pair through the amino acids at 12 and 13 positions, which is called 
the repeat variable diresidue (RVD, shown in red). Target sequences of TALEN pairs are 
typically 30–40 bp in length without the spacers. b, TALE–DNA co-crystal structure showing 
the interaction between the RVDs in TALE and the major groove of DNA. The amino-terminal 
repeats (represented as 0 and –1 in the box) contact 5ʹ T deoxynucleotide [44].  
 
a
b
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The one to one correspondence between the four RVD modules and the four nucleobases 
makes the design of new TALEs with the desired recognition sequence straightforward. This is 
an important advantage of TALEs over other types of DNA binding proteins, but the design of 
TALEs requires a T deoxynucleotide at the 5ʹ end of the target sequence which is recognized 
by two amino-terminal cryptic repeat folds. Thus, finding a target sequence with T at the 5ʹ end 
is always required, limiting the use of TALEs. Recently established TALE variants that 
distinguish other bases at the 5ʹ end would additionally increase the targetable sites [46,47]. 
Several online computer programs are available for the design of TALEs (Table 2.1). 
TALENs are composed of a TALE protein (DNA binding domain) connected to the 
NFokI cleavage domain. TALENs have been applied for modification of endogenous genes in 
various species, including yeast[48], viruses[49], plants, nematodes, insects, frogs, fish and 
mammals such as mice, rats [50] and pigs, in addition to the cultured mammalian cells [51,21]. 
 
2.3.3. CRISPR/Cas RNA-guided nucleases 
The newest tool of genome editing is known as clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas system. It is initially derived from the adaptive immune 
system of the bacterium Streptococcus pyogenes [52]. Since then, this system was found in 90% 
of archaea and 50% of bacteria. Bacteria use CRISPR/Cas system for the defense against the 
foreign viral DNA sequences (e.g. bacteriophage) [53]. CRISPR/Cas system is composed of a 
short RNA and Cas protein to target and cleave a specific DNA sequence, respectively. There 
are two classes of CRISPR/Cas [54]. Class 1 needs several Cas proteins but Class 2 only 
requires one Cas protein with many domains. The Class 2 CRISPR-Cas system is therefore, 
better for genome editing applications due to its simplicity [55].  
CRISPR-Cas9 is a widely used example of Class 2. It includes a highly effective Cas9 
enzyme. The Cas9 is an endonuclease protein with two nuclease domains: RuvC and HNH 
(Figure 2.7A). Thus, Cas9 acts as a pair of scissors to cleave DNA. CRISPR/Cas9 has two 
RNA components: a changeable CRISPR RNA (crRNA) and a fixed trans-activating crRNA 
(tracrRNA). The crRNA and the complementary tracrRNA form a double-strand RNA structure 
denoted as the guide RNA. These two RNAs can also be covalently linked together into a single 
guide RNA (sgRNA) (Figure 2.7B). 
Each crRNA contains a conserved repeat sequence and a variable spacer of around 20 
nucleotide length. This variable spacer should be complementary to the target DNA and it has 
to be selected so that a three base sequence, called PAM (protospacer adjacent motif) is present 
in the targeted DNA adjacent to it. The absence of the PAM sequence can influence the affinity 
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of the Cas9 enzyme towards the DNA/guide RNA complex. By the help of the sgRNA, Cas9 
cuts the matched DNA [56]. The RuvC domain cuts non-complementary DNA strand, including 
the PAM sequence, while the HNH domain cuts the complementary DNA strand hybridized to 
the crRNA spacer region. The schematic of the molecular mechanism of DNA cleavage by the 
CRISPR-Cas9 system is shown in (Figure 2.7 C).  
 
 
Figure 2.7. (A) Schematic diagram of the Cas9 protein consisting of two nuclease domains: the 
RuvC and the HNH domain. (B) The sgRNA consists of the tracrRNA and crRNA bound 
together covalently. The crRNA is composed of a 20bp protospacer element and additional 
nucleotides that are complementary to the tracrRNA. The tracrRNA hybridizes to the crRNA 
and binds to the Cas9 protein, forming the CRISPR-Cas9/sgRNA complex to edit genome. (C) 
Molecular mechanism of the CRISPR-Cas 9 system, Cas9 protein cleaves 3–4 
deoxynucleotides upstream of the PAM site [57]. The RuvC domain cuts the non-
complementary DNA strand, and the HNH domain cuts the complementary DNA strand. (D) 
Crystal structure of the catalytically active Streptococcus pyogenes Cas9 (PDB: 5F9R) in 
complex with the sgRNA and the dsDNA primed for target cleavage. Visualized with 
CHIMERA (UCSF) [58]. 
 
The targetable sites of this RNA guided nuclease are limited by the requirements of the 
PAM sequence, which should be NGG or NAG and the 5’ G deoxynucleotide. G shall be added 
to the 5’ end of the sgRNA if the initiation start site does not start with a G. The crystal structure 
of Streptococcus pyogenes CRISPR–Cas9 in complex with the single gRNA and its target 
double-stranded sequence is shown in (Figure 2.7 D). 
 
A B
C D
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Figure 2.8. Various strategies to deliver the CRISPR-Cas9 system [57]: (i) as a plasmid-based 
CRISPR-Cas9 system encoding the Cas9 protein and sgRNA within the same vector, or (ii) as 
a mixture of Cas9 mRNA and sgRNA or (iii) direct delivery of the Cas9/sgRNA complex in 
the cells.  
 
CRISPR-Cas9 can edit the genome by three different strategies (Figure 2.8). The most 
convenient strategy is using a CRISPR-Cas9 plasmid both expressing the Cas9 protein and 
transcribing the sgRNA [59]. Another approaches are delivering a mixture of the Cas9 mRNA 
[60] or Cas9 protein and the sgRNA [61]. The plasmid-based CRISPR/Cas9 system is a simple 
and convenient strategy to avoid the difficulty of the delivery of multiple components to the 
same cells and the plasmid-based CRISPR-Cas9 system is more stable than Cas9 mRNA with 
sgRNA. CRISPR-Cas9 is a promising tool in the treatment of genetic diseases by editing the 
mutated genes. RNA guided nucleases were already used to edit the genes in bacteria, eukaryota 
[59], zebrafish embryos [62], rats [63], non-human primates [60] and human pluripotent stem 
cells [64]. The current challenges focus on improving the specificity and delivery efficiency of 
the CRISPR-Cas9 system [57].  
 
2.3.4. The NColE7 nuclease domain (structure, function, consequences of mutations and 
regulation) 
Colicin E7 protein is a toxin produced naturally by Escherichia coli cells to protect 
themselves from the closely related bacteria, which contain the essential outer membrane 
receptors [65,66]. Colicin E7 consists of 567 amino acids including three functional domains: 
receptor binding (residues 3-308), membrane translocation (residues 288-446), and the toxic 
nuclease domain (residues 446-576). Under stress conditions, it binds to the receptor of the 
attacked cell and by the help of the translocation domain, the nuclease domain of the Colicin -
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E7 (NColE7) enters the cytoplasm to kill the cell by non specific degradation of the 
chromosomal DNA. The host cell protects itself against the nuclease activity by co-expression 
of immunity protein (Im7), which blocks binding of NColE7 to the DNA [67]. 
NColE7 is a member of the HNH nuclease family [68]. The name of HNH originates 
from the three underlined amino acids residues in EXHHX14NX8HX3H sequence. The HNH 
motif in NColE7 is the C-terminal catalytic part of the total 131 amino acids sequence. It binds 
to the minor groove of the DNA while the central helices of NColE7 bind to the major grove of 
the DNA (Figure 2.9). The HNH motif forms a metal-binding site by three histidine side chains 
(H544, H569, and H573). Zn2+ is the divalent metal ion, which coordinates to these amino acids 
under physiological conditions in a tetrahedral coordination geometry. Water molecule 
occupies the fourth coordination site. The metal ion is essential for the nuclease activity of 
NColE7. Zn2+ coordinates to the oxygen of the scissile phosphodiester bond, replacing the water 
molecule. H545 activates the water molecule for the nucleophilic attack at the scissile 
phosphodiester bond [69].The DNA cleavage results in 5’-phosphate and 3’-OH ends [70]. 
 
 
 
Figure 2.9. a, Crystal structure of NColE7 in complex with DNA (PDB: 3FBD). The orange 
sphere indicates the Zn2+-ion, which was not included in this structure, and it was placed as a 
result of the alignment with the 1M08 structure (chain A). PyMol’s rainbow coloring scheme 
was applied resulting in a color varied from blue (N-terminus) to the yellow (C-terminus). b,  
Sequence of NColE7, which is the C-terminal nuclease domain of the colicin E7 protein (446-
576) The N-terminal loop is written in blue and the HNH motif in green except the metal 
binding residues in red. The underlined residues are the name-giving HNH residues [71]. 
 
The role of the N-terminus of NColE7 was studied in detail [72,73]. It activates the 
nuclease by its positively charged amino acid residues sterically close to the catalytic site. R447 
is linked with Zn(II) ion through the phosphodiester group. R447 may also help the DNA 
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binding. Modifications or deletions in the N-terminal sequence affect the catalytic activity, and 
the W464A mutation destabilizes the NColE7 structure [74].  
 
2.3.5. NColE7-based integrated zinc finger nucleases 
Therapeutic applications of the ANs are still hampered by their off-target activity 
resulting in various levels of cytotoxicity [21,75]. One of the reasons might be the loss of the 
regulation of the catalytic activity, characteristic for the native enzymes. To overcome this 
hurdle, novel zinc finger ANs were designed in our laboratory, based on the NColE7 nuclease 
domain instead of the NFokI nuclease domain. Considering the properties of NColE7 with the 
emphasis of the need of the collaboration of its two termini in the catalytic action, the new ANs 
were expected to be more regulated.  
NColE7 was divided into two parts: the C-terminal domain, which is the catalytic center 
and N-terminal domain, which serves as an activator. These two parts were fused to the opposite 
termini of a zinc finger protein as shown in Figure 2.10. In this kind of artificial metalonuclease, 
the HNH-motif at the C-terminus is expected to have nuclease activity only in the presence of 
the positively charged N-terminal domain offering a positive allosteric control [76]. 
 
 
Figure 2.10. Schematic representation of the NColE7-based AN design strategy demonstrating 
the expected allosteric regulation. The inactivated C-terminal catalytic site is shown in green 
and the N-terminal activator is in pink. The specific DNA-binding domain (black) is a ZF 
protein that brings the above two parts together in space upon recognizing the target DNA 
sequence [77].  
 
 The new ANs consist of nuclease, DNA binding and regulator domains, rather than a 
simple chimera of two molecules in traditional ZFNs. Various series of NX-ZF-CY models 
were designed in which X is number of N-terminal amino acid residues and Y is the number of 
C-terminal amino acid residues of NColE7, ZF is a protein array of three fingers, the same 
published by Kim and Berg [78] (PDB code 1MEY). NColE7 and ZF domains were linked 
together by computer-designed peptide linkers. Three models of new ZFNs (N4–ZF–C45, N4–
ZF–C105 and N46–ZF–C45 were established (Figure 2.11).  
N-terminal
C-terminal
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Figure 2.11. The designed ZFN structures. The N-terminal part of NColE7 is red, the C-
terminal part is green, the ZF is blue, and the linkers are black. The grey spheres indicate Zn2+ 
ions. (a) N4–ZF–C45, (b) N46–ZF–C45, (c) N4–ZF–C105. The C- and N-termini of the ZFNs 
are marked by ‘C’ and ‘N’, respectively [79]. 
 
The three models have the allosteric regulator residues at their N-termini and the HNH 
motif at their C-termini such as the NColE7. These models were experimentally studied and 
have shown to exert slow but specific DNA cleavage. The reactivity of the new artificial 
nucleases followed the next order: N4–ZF–C105>N46–ZF–C45>N4–ZF–C45. These ZFN 
variants may have different activation mechanisms. The fusion of the C-terminal catalytic 
domain to the ZF domain could obviously increase its local abundance at the DNA, and the N 
terminal domain, fused to N-terminus of ZF domain acts as an activator for the catalytic domain. 
However, this kind of regulation of the catalytic domain was not effective in these nucleases. 
The expression and localization of NColE7-based ZFNs were studied in mammalian cells. The 
enzyme was detected in the cell nucleus, which is promising for future therapeutic applications 
in the human gene therapy [77], but further optimization is needed. 
 
2.4. The delivery of programmable nucleases 
 The success of the selected genome editing technique largely depends on the effectivity 
of the delivery of the nuclease into the specific target cells. It is a challenge to safely and 
effectively deliver the genome editing tool into the mammalian cells. We briefly summarize the 
most common delivery strategies. The delivery systems can be classified into non-viral and 
viral vehicles as shown in Figure 2.12.  
The non-viral methods include physical and chemical delivery. The most common 
physical methods are electroporation, microinjection, induced transduction, mechanical cell 
deformation, and hydrodynamic injection. 
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Figure 2.12. A summary of the types of delivery routes. The ANs may be delivered as a DNA 
or mRNA molecule encoding for the protein/RNA, or it may be delivered as a functional 
protein/ribonucleoprotein (RNP). Regardless of cargo format, the largest challenge lies in 
delivering the cargo across the cell membrane. A variety of viral and nonviral methods have 
been derived to achieve successful delivery across the cell membrane. AAV: adeno-associated 
virus; AuNP: gold nanoparticle; CPP: cell-penetrating peptide; LNP: lipid nanoparticle; NLS: 
nuclear localization sequence [80]. 
 
For chemical delivery lipid nanoparticles, polymer nanoparticles, cell penetrating peptides, 
DNA nanostructures, gold nanoparticles and further newly developed vehicles can be applied. 
Viral delivery systems include adeno-associated virus (AAV) and lentivirus (LV) vehicles. 
 
2.4.1. Non-viral delivery methods  
Non-viral delivery of programmable artificial nucleases has shown high efficiency 
because of its safety, large loading capacity and low cost production. Non-viral delivery 
systems have shown low level of the off-target effects [81]. These advantages make them 
attractive for delivery applications. The physical methods are widely applied in the laboratory 
but less used for the in vivo applications because they are based on physical modifications of 
the cells. The chemical vehicles became more promising for the in vivo applications.  
 
2.4.1.1. Physical delivery methods 
Physical delivery methods depend on making a simple pierce in the cell membrane for 
the direct injection of the cargo into the target cells.  
a) Electroporation. Electroporation is a process of introducing nucleic acids or proteins into 
bacteria or other cells using a pulse of electricity to briefly open the pores in the cell membranes. 
The disadvantages of electroporation are that plasmid DNA is only inserted into around 0.01% 
Protein/RNP-CPP/NLS
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of the target cells and it also leads to high level of cell death. Nevertheless, electroporation has 
newly been used to deliver CRISPR-Cas9 based plasmid to cancer cells, embryonic stem cells 
and CD34+ stem cells [82,83]. Editing efficiencies of 87% and 94% were achieved in induced 
pluripotent stem cells and Jurkat T cells, respectively via the electroporation of RNPs, but lower 
efficiency in induced pluripotent stem cells (20% and 32%) and Jurkat T cells (63% and 42%) 
was achieved using plasmid-based CRISPR-Cas9 system and the Cas9 mRNA/sgRNA, 
respectively [84].  
b) Microinjection. Microinjection is a technique to deliver the DNA or protein into a single cell 
by direct injection using glass micropipette. Microinjection of CRISPR-Cas9 was used to edit 
genes in different types of cells [85,86]. Although microinjection is very simple and accurate it 
requires a high level of manual skills not to induce cell damage. Another disadvantage is that 
only a single cell can be targeted in each injection, so this method is only suitable for a limited 
number of cells. 
c) Induced transduction by osmocytosis and propanebetaine (iTOP). Proteins and other 
compounds can be delivered into the cells by iTOP method by using hyperosmolar buffer 
consisting of sodium chloride and propanebetaine (a transduction compound). iTOP method is 
effective for intracellular delivery of the Cas9 protein and sgRNAs separately, or direct delivery 
of RNPs. But iTOP has limited use because it needs high salt concentration for dissolving the 
proteins, which is not suitable for in vivo applications [57]. 
d) Mechanical cell deformation. Mechanical deformation induces the disruption of the cellular 
membrane to uptake the cargos through the passive diffusion. Mechanical cell deformation is 
an effective delivery with low death rate [87]. A microfluidic device with optimized physical 
shrinkage was used successfully to deliver a plasmid-based CRISPR-Cas9 system in vitro and 
achieved 90% knockout efficiency of EGF in MDA-MB-231 (breast cancer cells) [88], but it is 
limited to in vitro use only.  
e) Hydrodynamic injection. Hydrodynamic pressure is induced by rapid and sudden injection 
of a high volume of nucleic acid solution. This pressure leads to the temporary formation of 
pores in the membrane allowing the entry of the nucleic acids into the cells [89]. This method 
is simple and effective [90].  
 
2.4.1.2. Chemical delivery methods 
Chemical systems are in general nanomeric complexes, more widely used than physical 
methods. They include compaction of negatively charged nucleic acid by mostly cationic 
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particles. These nanomeric complexes can enter the cells easily and release the nucleic acids 
[91]. Chemical delivery systems have low toxicity and antigenicity compared to viral vectors. 
a) Lipid nanoparticles. Lipid nanoparticles are common and effective delivery systems for the 
nucleic acids. The negative nucleic acids are encapsulated or complexed with the positively 
charged lipid nanoparticles through electrostatic attractions. The lipid vector protects the 
nucleic acids from the nuclease degradation and immunological response. It can be modified 
with polyethylene glycol (PEG) to increase its lifetime inside the blood circulation system and 
can be modified also by specific antigen to target the specific tissue.  
Cationic systems consist of either a single synthetic cationic amphiphile (cytofectin), 
such as DOTAP, DOTMA, DOSPA, DMRIE and DC-cholesterol or a combination of a cationic 
amphiphile and a neutral lipid, such as DOPE, DSPC and cholesterol (Figure 2.13). These 
neutral helper lipids enhance the transfection efficiency through destabilization of the 
endosomal membrane to facilitate lipid exchange and membrane fusion between lipoplexes and 
endosomal membrane leading to higher gene expression [92,93]. 
 
 
Figure 2.13. Chemical structures of cationic and neutral lipids. Liposomal formulations used 
for DNA delivery typically include a mixture of a neutral lipid and a cationic lipid. Cationic 
lipids (such as DOTMA, DOSPA, DOTAP, DMRIE and DC-cholesterol) have an active role 
in DNA binding and transfection. They are characterized structurally by a cationic head group, 
a hydrophobic tail and a linker region. Neutral lipids (such as the phospholipids DSPC and 
DOPE, and the membrane component cholesterol) function as ‘helper lipids’ to further enhance 
nanoparticle stability and overall transfection efficacy. 
 
The cationic lipid nanoparticles were utilized as in vitro delivery vectors for ZFNs [94] 
and have been used in several therapeutic applications of the CRISPR/Cas9 [95]. Lipofectamine 
is the most common commercial optimized delivery system. Genome editing efficiency using 
lipid nanoparticles can more than 70% in HEK cells. These delivery systems have some 
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drawbacks such as the poor stability and rapid clearance, as well as inflammatory or anti-
inflammatory responses [96]. 
b) Polymer nanoparticles 
Cationic polymers have high DNA condensing ability. There are several types of 
cationic polymers such as poly(ethylenimine) (PEI), poly(L-lysine) (PLL), poly[2-
(dimethylamino) ethyl methacrylate] (PDMAEMA), and polyamidoamine (PAMAM) 
dendrimers (Figure 2.14). 
PEI is one of the leading reagents because of the high concentration of positively 
charged ammonium groups interacting strongly with the negatively charged DNA. It forms 
stable and condensed DNA/PEI complexes and protects the genetic material from the enzymatic 
degradation. PEI is synthesized in linear and branched form. There is a relationship between 
the length of the polymer, gene delivery efficiency, and toxicity. As the length of the polymer 
increases, so its efficiency increases because the net positive charge of it also increases and it 
is able to bind DNA strongly [97,98]. Recently branched PEI was used to deliver plasmid-based 
CRISPR-Cas9 [99].  
 
Figure 2.14. Chemical structures of polymeric vectors. PEI: poly(ethylenimine); PLL: poly(L-
lysine); PDMAEMA: poly[2-(dimethylamino) ethyl methacrylate]; PAMAM: polyamidoamine 
[100].  
 
Modification of PEI by polymers and/or ligands has recently been investigated to 
overcome the increasing cytotoxicity with increasing molecular weight and aggregation in the 
case of high ionic strength [101,102]. Changing its physicochemical properties is aimed to 
enhance biocompatibility and transfection efficiency [103,104]. 
c) Cell-penetrating peptide (CPP). CPPs typically consist of 5–30 amino acids including 
several arginine and lysine residues, which are positively charged at the phsiological pH. They 
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can cross the cellular membrane by translocation or penetration [105]. Cas9 protein was 
covalently attached to a CPP and the sgRNA conjugated with another CPP by electrostatic 
interactions for in vitro expreiments. The following disadvantages can limit the applications of 
CPPs: (i) the conjugated protein can be degraded by the proteases; (ii) CPP cannot target 
specific cells; (iii) this method needs chemical conjugation [106]. 
d) DNA nanostructure. DNA nanostructures have several applications in medicine, such as 
imaging and drug delivery. DNA nanostructure is a sphere like DNA structure, formed by base 
pairing of small DNA sequences. It needs a high amount of DNA. DNA nanostructures called 
nanoclew are being developed by rolling circle replication (RCR). PEI can be added to this 
nanoclew to be positively charged to improve the endosomal escape and cellular uptake. 
Nanoclew has been used in 2015 to deliver the Cas9 protein and sgRNA complex and it 
achieved a mutation efficiency around 36% [107]. The main disadvantages of the nanoclews 
are their complicated assembly and the possibility of immunological response. 
e) Gold nanoparticles (AuNP). AuNP has been used as a new delivery vector for Cas9/sgRNA 
ribonucleoprotein complexes (RNPs), achieving around 90% transfection and 30% genome 
editing efficiency [108]. It is a very promising AN delivery tool, but it is limited for the in vivo 
application due to the toxicity at applied concentrations.  
 
2.4.2. Viral delivery methods  
The viral delivery vectors can be used to deliver nucleic acids for gene therapy purposes 
with high delivery efficacy but they have many limitations such as carcinogenesis, 
immunogenicity, limited DNA packaging size and difficulty in production [109]. 
a) Adeno-associated virus (AAV). The genome of AAV is composed of a single DNA strand 
about 4.7 kb. It is widely used for the gene therapy because it does not cause diseases in the 
humans, has moderate immunogenicity and has a wide range of serotypes so it can infect 
various cells [110]. The first promising gene therapy trial with AAV was in 2012 for treatment 
of lipase deficiency [111]. AAV was used to deliver ZFNs. The transfection efficiency of 
AAV/ZFN particles was investigated in vitro and in vivo [112].  
It has been used also for delivery of CRISPR/Cas9. The sequence encoding the 
Streptococcus pyogenes Cas9 protein and sgRNA is approximately 4.2 kb.The challenge for 
AAVmediated CRISPR-Cas9 delivery is the packaging limit of AAV (approximately 4.5 kb) 
[113]. For this reason, CRISPR-Cas9 system was delivered by alternative ways: (i) AAV was 
used to deliver the sgRNA only into cells modified to express Cas9 protein by using the 
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microinjection method [114]; (ii) another method was the packaging of the Cas9 and sgRNA 
separately into two AAV particles but this is quite complex procedure [115]. 
b) Lentivirus (LV). Lentivirus is a widely used vector for gene therapy due to its high infection 
efficiency. It can infect even the non-dividing cells, has mild immunogenicity and can be used 
both for the in vitro and in vivo applications. The size of LV is approximately 80-100 nm, being 
better for large insertions and suitable for the CRISPR/Cas9 delivery [110]. An advanced type 
of LV called integrase-defective LV was utilized in ZFN-based genome editing in human stem 
cells [116].  
Viral particles with the packaged Cas9 and sgRNA were used to infect HEK293T cells. 
One plasmid expressed the proteins and enzymes which are necessary for viral particle 
formation and another plasmid encoded the CRISPR/Cas9 system [117]. Promising results were 
obtained in the chronic hepatitis B virus (HBV) treatment by the lentivirus-based CRISPR/Cas9 
system [118]. It was utilized also for development of a mouse model with myeloid leukemia, 
targeting genome regions of herpes simplex virus-1 and to mutate genes in primary immune 
cells of mouse [119]. 
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3. AIMS AND OBJECTIVES 
 
The aim of the research conducted in the Bioinorganic Chemistry Research Group of 
the Chemistry Institute at University of Szeged is to develop an effective artificial nuclease as 
a promising molecular tool for gene therapy. I have joined this research team in 2016. At that 
time the research has focused on the design of a novel zinc finger artificial nuclease based on 
the NColE7 nuclease domain instead of the NFokI nuclease domain. Therefore, my work is 
aimed at optimization of the newly designed ZFNs for targeting oncogenes in cancer cells, as 
well as at comparison of these artificial nucleases with the currently widely used CRISPR/Cas9 
system. Furthermore, we decided to develop a novel drug delivery system to increase the 
efficiency of the designed artificial nucleases by their delivery into the target cells. 
The summary of my aims is shown in Figure 3.1 which explains my interdisciplinary 
research including chemistry and biology. According to this scheme, my research consists of 
three main steps: (i) optimizing of a promising artificial nuclease, (ii) development of an 
effective drug delivery system and (iii) studying of the behavior of these systems in cancer cells.  
 
  
 
Figure 3.1. The schematic demonstration of the aims of my PhD research project. 
 
 
C45-ZF-N85 CRISPR/Cas9 
Loading of the gene of 
the artificial nuclease
Optimization of zinc finger-NColE7 
based artificial nucleases for
specificity and regulation.
Genome Editing
Cancer cells Epidermal Growth Factor Receptor oncogene
Optimization of the DNA targeting
sequence (gRNA) for finding an 
efficient site for knock-out of the
oncogene. 
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During my PhD studies I focus on the following objectives: 
 
1- Construction of a new protein expression system for effective purification of artificial 
nucleases 
The production of proteins in high yield and purity is usually difficult and requires 
multistep chromatographic methods often leading to a significant loss of target proteins. In our 
laboratory, the synthesis of proteins with precisely determined sequences is very important 
because the computer design of artificial nucleases requires the reproduction of the protein 
sequence. Therefore, it is a topical issue to develop purification procedures for the designed 
proteins with precisely determined sequences. A strategy was elaborated by means of which 
the designed artificial nucleases can expressed and purified by immobilized metal ion affinity 
chromatography, but without any additional remaining amino acids at the termini of the protein 
after removal of the hexahistidine affinity tag. This system can also be applied for the 
expression of purification of native proteins and can be used with various C-terminal affinity 
tags.  
 
2- Improving of the newly designed NColE7-based zinc finger nuclease  
There is a chance that the metal ion binding hexahistidine affinity tag may influence and 
thus, modulate the catalytic activity of the NColE7 metalloenzyme, used as the catalytic center 
of the new artificial nuclease. Therefore, we decided to explore this effect for development of 
a novel regulation mechanism. The regulation may also be achieved in the novel zinc finger 
nucleases by inactivating the nuclease domain itself in the absence of a specific DNA target 
sequence. To better understand the regulation mechanisms, and to further optimize the artificial 
nucleases, the expression and purification of the promising AN variant (C45-ZF-N85), its 
mutants, as well as 6×His tagged NColE7 mutants was foreseen followed by the study of their 
solution structure by circular dichroism spectroscopy and their specificity and/or regulation by 
in vitro catalytic experiments. 
 
3- Design of CRISPR/Cas9 artificial nucleases for oncogene targeting  
I planned to apply the CRISPR/Cas9 system to target epidermal growth factor receptor 
(EGFR) oncogene in A549 human lung cancer cells. Designing various recognition sequences 
within the gene would allow for detection of the most efficient artificial nuclease target sites, 
which can also be targeted by the new NColE7-based ANs upon redesign of the ZF domain. 
This would also allow for comparison of the different ANs.  
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4- Development of a novel drug delivery system for artificial nucleases 
The success of the selected genome editing technique is influenced by the effectivity of 
the delivery system used to carry the nuclease to the specific target cells to induce its therapeutic 
effect. Improvement of the delivery and specificity of the ZFNs and CRISPR-Cas9 system 
could help to overcome current challenges, and promote the artificial nuclease technology to be 
used therapeutically. Chemical delivery methods are being considered to be the most promising. 
For this purpose, we decided to synthesize a water-soluble lipopolymer from a high molecular 
weight poly(ethylenimine) by cholesterylation, to characterize its DNA loading properties and 
study its gene delivery i.e., transfection efficiency in cancer cells. 
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4. METHODS 
 
4.1. Recombinant protein production 
In this work, proteins were produced from different recombinant DNA elements for 
various experiments. Proteins produced with the recombinant DNA technology are the so-
called recombinant proteins. The first step includes the genetic recombination to bring together 
genetic material from multiple sources thereby, creating recombinant DNA sequences that are 
naturally not found in the genome, and the DNA cloning. Then, the production of recombinant 
proteins follows, including the protein expression from the recombinant DNA in cells, the 
protein purification by a specific method and quality control of the purified proteins.   
 
4.1.1. Recombinant DNA technology 
Recombinant DNA technology allows DNA of interest to be produced through artificial 
means. It also involves specific mutations of the DNA sequence by polymerase chain reaction 
(PCR), insertion of the mutated DNA sequence into a specific carrier plasmid DNA, and 
producing copies of it within the bacterial cells as shown in Figure 4.1. Each step is explained 
below. 
 
 
Figure 4.1. Schematic illustration of recombinant DNA production. 
Antibiotic
resistance 
gene
Restriction site
Gene of interest
Foreign DNA
Cleavage by specific 
restriction enzyme
1
4
3
2 Ligation (T4 Ligase) 
Transformation into E coli cells
Multiplication
Bacterial chromosome
DNA purificationCulture
5
27 
 
4.1.1.1. Polymerase chain reaction (PCR) 
For the production of specific proteins or their modified versions, first their genes are 
obtained and amplified by polymerase chain reaction (PCR). This method is used also to insert 
restriction sites into the target DNA sequence, so that it can be digested by a specific restriction 
endonuclease There are five main ingredients of the PCR reaction mixture: 
• DNA template. 
• Two (forward and reverse) primers, which are short oligonucleotides essential for initiating 
the polymerase enzyme to start the amplification step, by hybridizing to the single-strand 
template. 
• The mixture of the four deoxynucleoside triphosphates (dNTPs), which are the building 
blocks of DNA (dATP, dTTP, dGTP, and dCTP) 
• Heat-stable DNA polymerase enzyme (usually Taq polymerase from Thermus aquaticus). 
• A buffer, that also contains Mg2+ to keep the reaction in the optimal condition. 
PCR involves periodic heating and cooling of the reaction mixture by a thermal cycler 
instrument. Three main steps of a cycle are: denaturation, annealing, and extension (Figure 
4.2). First, the PCR reaction mixture is heated to 94-95C for 15-30 seconds to denature the 
dsDNA template into two ssDNA strands, which act as templates for the formation of new DNA 
strands. Then the temperature is decreased to a suitable value for the primers to bind to their 
complementary sequences on the single-strand DNA – usually between 50 and 60C for 10-30 
seconds. This temperature is adjusted considering the melting temperature of the primers used.  
 
 
Figure 4.2. Principle and major steps of the Polymerase Chain Reaction (PCR). 
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The forward and reverse primers allow the two complementary single strands to be 
extended from their 5’ end toward the 3’ end, when the temperature is increased again to 72C, 
suitable for Taq DNA polymerase enzyme function. So it can attach to the primer and add the 
nucleotides to the growing strand at its 3’ end, resulting in a new double-strand DNA molecule. 
The duration of this step depends on the length of the DNA to be amplified. Copying of a 1 kbp 
DNA takes ~1 minute. These three steps of the thermal cycling are repeated ~30 times. Since 
the new DNA molecules behave as templates in the subsequent cycles, the amplification is 
exponential. The PCR product resulted from this reaction is checked by the gel electrophoresis. 
The successfully amplified PCR product can be used for cloning into a carrier circular DNA 
molecule. 
 
4.1.1.2. Digestion and ligation processes  
Specific restriction sites are designed within the primer sequences and are added to the 
termini of the gene of the target protein through the PCR. The resulted gene can be inserted into 
a specific carrier, so-called plasmid DNA (pDNA). The plasmid is a circular double-strand 
DNA molecule, originally isolated from the bacterial cells. It consists of a few thousands of 
DNA base pairs. These plasmids have been modified for the purpose of molecular cloning in 
the laboratory. Both the target gene and the plasmid are digested by a restriction endonuclease 
at a specific sequence to get double-strand DNAs with sticky ends (short, single-strand 
overhangs). Using the same restriction enzyme these sticky ends will be complementary to each 
other.  
The cleaved target gene is ligated into the linearized plasmid by the ligase enzyme, 
which covalently joins the phosphate backbone of DNAs with blunt or compatible sticky ends. 
This ligation process results in a recombinant DNA molecule containing the gene of the target 
protein. This ligation reaction needs the optimization of the temperature for bringing the DNA 
ends together, and then ligate them. We applied incubation for 1 hr at 16°C and then lowering 
the temperature to 4°C overnight. The plasmid and insert genes should have an optimal molar 
ratio (1/6) in the reaction for effective ligation.  
 
4.1.1.3. Transformation of bacteria 
The ligated plasmid is introduced into harmless E. coli bacteria used in labs, in a process 
so-called transformation. This is usually done by a heat shock treatment. The plasmid contains 
an antibiotic resistance gene that enables the bacterial cells to survive in the presence of a 
specific antibiotic, so only the bacteria containing the plasmid can grow without any 
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contamination. A bacterial cell will grow into a small colony carrying a single type of plasmid. 
Not all the colonies contain the modified plasmid, because in some cases the ligation fails. So 
the plasmid DNA is purified from several colonies. This involves the culturing of the bacteria 
in a suitable liquid medium, the bacterial cell lysis, DNA extraction and precipitation by 
ethanol. The plasmids are checked for the successful ligation by different methods like PCR, 
agarose gel electrophoresis, restriction enzyme digestion, and DNA sequencing. 
 
4.1.2. Protein expression and purification 
Several types of expression vectors (plasmids) are available for production of 
recombinant proteins. The pET-21a commercial plasmid (Figure 4.3) and its modified versions 
were used in this study. 
 
Figure 4.3. The schematic representation of the pET-21a plasmid. The cloning site contains 
unique restriction sites. The ampicillin resistance gene allows for the selection of bacteria 
against the antibiotic.  
 
The pET-21a plasmid contains a lac (lactose) operon which is one of the most common 
systems used for the protein expression control, see the map of pET-21a plasmid in Appendix 
A.1.  The lac repressor protein (LacI) senses the presence of lactose, which is the inducer of 
lactose operon as it triggers the transcription of the lac operon to express the protein in 
BL21(DE3) E. coli strain. Isopropyl β-D-1-thiogalactopyranoside (IPTG) is a structural mimic 
of lactose used as an inducer for the protein expression. It binds to the lac repressor then 
activates the transcription of the gene in the lac operon. IPTG reagent is used instead of the 
lactose because the lactose is degraded by β-galactosidase enzyme during the bacterial 
metabolic pathway but the IPTG is not, since it contains sulfur atom preventing the enzymatic 
hydrolysis. Therefore, the concentration of IPTG remains constant and the protein expression 
will not be decreased or inhibited resulting in overexpression of the target protein. IPTG is 
added when the bacterial growth in the LB medium causes an optical density (OD) of ~ 0.6–
0.8. 
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The pET-21a plasmid contains DNA sequence coding for six histidine residues fused to 
the C-terminus of the gene of the recombinant protein, resulting in the expression of the protein 
with a poly-His tag. These His-tagged proteins are purified by immobilized metal ion affinity 
chromatography (IMAC). Both metal affinity and cation exchange chromatography were 
applied in this work. 
 
4.1.2.1. Immobilized metal affinity chromatography (IMAC) 
IMAC is a rapid purification method of the proteins with oligohistidine affinity tags. 
The desired metal ion used in the IMAC can be immobilized by different supports, such as 
magnetic particles or beaded agarose derivatized by chelating groups. These supports are used 
for binding and purification of proteins. Nitrilotriacetic acid (NTA) and iminodiacetic acid 
(IDA) are common chelators used as ligands. NTA-agarose resin loaded with the desired metal 
ion (Ni2+) was used in this work. The resin is packed into a suitable column and serves as the 
stationary phase in the fast protein liquid chromatography (FPLC), while the resin can be used 
for batch purification, as well. The oligohistidine tags can bind to the IMAC resin in neutral 
buffer conditions. The binding and washing buffers consist of Tris-HCl with a low 
concentration of imidazole (competing ligand) to prevent the non-specific protein binding. The 
His-tagged protein is eluted from the IMAC column by using high imidazole concentration.  
In this work, IMAC Sepharose 6 Fast Flow column was used. It consists of highly cross-
linked 6% spherical agarose and has a high protein binding capacity. The binding capacity is 
metal ion- and protein dependent. The medium is easy to pack and use, and its high flow 
properties make it excellent for scaling up. 
 
4.1.2.2. Cation exchange chromatography 
Cation exchange chromatography is used to separate molecules having net positive 
surface charges on a negatively charged ion exchange resin. The proteins and enzymes 
interacting with DNA, such as the zinc finger nucleases designed in our laboratory are 
positively charged. Thus, cation exchange chromatography was used in this work. All ion 
exchange chromatographies rely on electrostatic interactions between the resin functional 
groups and proteins of interest. The conditions of cation exchange chromatography should be 
adjusted to best suit the protein of interest, and the ion exchange resin chosen. The pH and ionic 
strength greatly affect protein binding to the resin. 
To perform the protein purification by this method, first the column is equilibrated with 
a suitable buffer. After the protein sample is loaded onto the column, it is washed to remove the 
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unbound protein molecules and impurities. Finally, the target protein is eluted from the column 
by gradient elution changing the buffer pH or the ionic strength. The gradient elution is 
optimized for the best elution conditions. Once the elution profile of the protein of interest has 
been established and it is known at what ionic strength and pH a protein elutes, a step elution 
can be used to speed the purification process. After all remaining protein has been eluted from 
the resin, the column is equilibrated in low ionic strength buffer.  
In this work, a Sepharose SP Fast Flow column was used. In the Fast Flow ion exchanger 
columns 90 µm agarose beads serve as a matrix, that is highly crosslinked (6%) providing high 
physical and chemical stability and can be used with high flow rates in a wide pH-range. 
 
4.2. Characterization of proteins 
4.2.1. SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is widely used 
for the separation of proteins based on their molecular weights. The polyacrylamide gel consists 
of acrylamide and N,N’-methylenebisacrylamide which form a highly crosslinked matrix. The 
gel polymerization is initiated by a free radical mechanism: sulfate radicals are provided by 
ammonium persulfate. N,N,N′,N′-Tetramethylethylenediamine (TEMED) stabilizes the 
radicals for the polymerization reaction.  
The protein samples are denatured before loading to the gel by a buffer including 2-
mercaptoethanol (ME) or dithiothreitol (DTT) and SDS and heating this mixture at 
temperatures > 90C for a few minutes. ME or DTT reduces the disulfide bridges that might be 
present between the cysteine residues. SDS denatures and linearizes the protein and provides a 
net negative charge proportional to the Mw by adsorbing to the hydrophobic parts of the protein. 
Specific buffers are used to conduct the electric current between the cathode and the anode 
through the gel. The denatured samples are loaded onto the gel, which is placed in 
electrophoresis buffer. A voltage around ~100 V is applied. The proteins sorted by the size are 
visualized by staining with Coomassie Brilliant Blue dye, and destaining by using a solution 
composed of methanol and glacial acetic acid. The molecular weight and the concentration of 
the protein band can be estimated by using a mixture of a known size proteins as a marker. 
 
4.2.2. Mass spectrometry of metalloproteins 
Mass spectrometry (MS) is an analytical technique that reveals the molecular mass by 
ionizing the chemical compounds and sorting them based on their mass-to-charge ratio (m/z). 
The so-called soft ionization techniques like ESI (electrospray ionization) and MALDI (matrix-
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assisted laser desorption/ionization) are used for the study of biological macromolecules [120]. 
The intact molecular ions are generated in the ionization chamber and transferred to the mass 
analyzer, which sorts the ions according to their m/z value. The separated ions are then passed 
to the detector systems to measure their relative amounts, and the results are shown as a mass 
spectrum [121]. 
 
 
Figure 4.4. Schematic representation of the electrospray ionization process. 
 
In an ESI ion source, a high voltage is applied to a steel capillary to generate charged 
droplets containing the analyte molecules. When solvent evaporates, charge accumulates until 
the Rayleigh limit is reached and the droplet undergoes Coulomb fission into smaller droplets. 
This process continues until the naked charged analyte ions enter the mass spectrometer (Figure 
4.4.). The actual voltage required depends on the needle's inner diameter (i.d.) as well as the 
solvents which make up the solution. Typical nanospray instruments use fused silica or glass 
capillaries with orifice inner diameter < 10 µm from which solution normally flows at rates < 
100 nL/min. Micro-electrospray devices use larger capillaries (10 µm < i.d. < 100 µm) with 
slightly higher flow rates (100 nL/min < flow rate < 500 nL/min).  
The ESI process produces multiply charged ions of the same protein molecule due to 
protonation of the basic sites (in positive ion-mode) or deprotonation of acidic sites (in negative 
ion-mode) denoted as (M+zH)Z+and (M–zH)Z–, respectively [122]. An example of a multiply 
charged spectrum is given in Figure 4.5.  
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Figure 4.5. A hypothetical multiply charged spectrum. 
 
From this spectrum the molecular mass of the analyte molecule can be mathematically 
determined using a simple algorithm for two adjacent peaks differing by one charge state: 
𝑚1 =
𝑀−𝑧1𝑀𝐻+
𝑧1
       (4.1) 
𝑚2 =  
𝑀 − 𝑧2 𝑀𝐻+
𝑧2
 =  
𝑀 −(𝑧1 +1)𝑀𝐻+
𝑧1+1
    (4.2) 
where m1 and m2 are m/z values of two adjacent peaks in the spectrum with the charge states z2 
= z1+1. The molecular mass of an analyte is M and MH+ is the mass of a proton. Solving the 
Equations 4.1 and 4.2 for z1 yields Equation 4.3 for negative ion mode: 
            𝑧1 =
𝑚2+ 𝑀𝐻+
𝑚2− 𝑚1
       (4.3) 
Substitution of this value into equations 4.1 or 4.2 provides the value for the molecular 
mass of an analyte, M. This process can then be repeated for different pairs of adjacent charge 
states from the spectrum, and hereafter the molecular mass is determined by averaging the 
obtained values. Using this algorithm the m/z for the multiply charged ion is converted to the 
mass of the zero-charged molecule [123]. This common algorithm assumes that all charge 
present on an ion is due to an excess of protons in positive ion-mode or a deficit of protons in 
a negative ion-mode. This assumption is true for the apo-proteins while for the metalloproteins 
additional considerations need to be taken into account [124]. Metalloproteins are interesting 
targets for mass spectrometric analysis because the stoichiometry and oxidation state of the 
metal or metal-cluster can be obtained, even though the information that is sought are 
determined by the ability of protein molecules to form multiple-charged ions.  
In this study, intact protein analysis was performed by mass spectrometry (MS) on an 
Orbitrap EliteTM (Thermo Scientific) Hybrid Ion Trap-Orbitrap Mass Spectrometer coupled 
with a TriVersa NanoMate (Advion) chip-based electrospray ion (ESI) source. Prior to ESI-MS 
measurements, we performed buffer exchange on the protein to 10 mM NH4HCO3 pH 8.0 buffer 
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using Amicon Ultra 0.5 mL centrifugal filters with 3 kDa molecular weight cut-off. All the 
masses were measured in the Orbitrap mass analyzer in positive ion mode with 120 k resolution 
(R = 120,000 at 400 m/z). Protein intact masses (single protonated forms) were determined by 
deconvolution using the Freestyle 1.6 software tool (Thermo Scientific). 
 
4.2.3. Study of protein solution structure by circular dichroism spectroscopy 
Circular Dichroism (CD) spectroscopy is a technique used for the analysis of the 
conformation, structural stability and interaction of chiral macromolecules (proteins, DNA) in 
various conditions (temperature, ionic strength, and presence of interacting agents). [125-127]. 
The difference in absorption of the left and right circularly polarized light components by the 
sample is measured. Using the Beer-Lambert law the concentration of the sample can be 
obtained (Equation 4.4).  
A = AL – AR = Llc – Rlc = lc     (4.4) 
Where L is left and R is right, ε is the molar absorption (an intrinsic property of the molecule) 
in M–1cm–1, l is the optical path-length in cm, and c is concentration in M. The difference in 
absorption results in an elliptically polarized light, characterized by the ellipticity (θ), in 
milidegrees (Figure 4.6).  
 
Figure 4.6. Elliptically polarized light (violet) is composed of unequal contributions of right 
(blue) and left (red) circular polarized light. 
 
Elipticity and the absorption difference are related by Equation 4.5. 
∆𝐴 =
𝜃
32980
        (4.5) 
In the case of proteins, the results are usually expressed as the mean residue molar 
ellipticity, [θ] (Equation 4.6).  
[𝜃] =
𝜃 100 𝑀𝑤
𝑐 𝑙 𝑛
       (4.6) 
Where θ is the ellipticity in degrees, l is the optical path in cm, c is the concentration in 
g/ml, Mw is the molecular weight and n is the number of amino acid residues in the protein. The 
mean residue molar ellipticity [θ] is given in degcm2dmol–1. CD investigates the secondary 
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structure of proteins through the induced asymmetry of the peptide chromophores in the 170–
250 nm wavelength region. Hypothetical proteins with all α-helix, all β-sheet or a random coil 
show characteristic far-UV CD spectra (Figure 4.7). Using this information several algorithms 
have been developed to determine the secondary structure fractions of proteins from their CD 
spectra.  
 
 
Figure 4.7. The CD spectra characteristic for alpha-helix, beta-sheet, and random coil. Each of 
the three basic secondary structures of a polypeptide chain (α-helix, β-sheet and random coil) 
show a distinct CD spectrum [128]. 
 
In our experiments, circular dichroism spectra were recorded both on a Jasco J-815 
spectropolarimeter or at the CD1 beamline of the storage ring ASTRID at the Institute for 
Storage Ring Facilities (ISA), University of Aarhus, Denmark [129,130]. Camphor-sulfonic 
acid served as a calibration material for the instrument. All spectra were recorded using 1 nm 
steps and a dwell time of 2 s, using quartz cells (SUPRASIL, Hellma GmbH, Germany) with a 
0.1 mm optical length, in the wavelength range of 180–300 nm. Prior to the measurements, the 
protein solutions were dialyzed or ultrafiltrated against a 10 mM HEPES, pH 8.2 buffer. Spectra 
were baseline-corrected by using the spectrum of water or buffer. 
 
4.2.4. Determination of protein concentration 
The measurement of protein concentration in an aqueous sample is essential for further 
investigations, applications ranging from circular dichroism spectroscopic analysis to 
enzymatic studies and biopharmaceutical analysis. Spectrophotometric protein quantitation 
assays rapidly determine the concentration of proteins either relative to a standard e.g., Lowry, 
Bradford, Comassie blue staining, biuret methods, or using estimated molar absorption 
coefficients [131,132]. In our lab, common UV absorption spectroscopic and Nanodrop 
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instruments are used to measure the protein concentration. The simplest and most direct assay 
method for protein concentration determination in solution is to measure the UV absorbance at 
280 nm. Amino acids containing aromatic side chains (i.e., tyrosine, tryptophan and 
phenylalanine) exhibit strong UV-light absorption. Therefore, proteins and peptides absorb 
UV-light in proportion to their aromatic amino acid content and total concentration. The 
concentration is calculated using Beer’s law. The molar absorbance () is estimated based on 
the amino acid sequence using Expasy’s ProtParam tool (http://web.expasy.org/protparam/).  
Protein concentration can be detected also at wavelength 205 nm by using short path 
length cells, in the case of a sample of small concentration (< M). A large number of peptide 
bonds within proteins make such measurement more sensitive and display less protein-to-
protein variability than the measurements at 280 nm. However, this method is very sensitive to 
interferences from impurities and buffer components. Therefore, the protein sample has to be 
very pure and the composition of the buffer used for the reference measurement has to be 
precisely defined.  
 
4.3. Catalytic activity assays 
 Catalytic experiments were performed to study the nuclease activity. Most commonly a 
plasmid DNA was applied as a substrate. The plasmid DNA has various forms with different 
mobility properties in an agarose gel. The double-strand DNA cleavage converts the 
supercoiled form into linear form, while the single-strand cleavage results in an open circular 
form. The catalytic reactions were performed under many different conditions, varying the 
concentration of the substrate and the enzyme, metal-to-protein molar ratios, ionic strength, 
time, etc. The reaction mixtures were incubated at 37°C and the catalytic reaction was stopped 
by adding SDS to a 1% (m/V) final concentration. Then the DNA cleavage was checked by 
agarose gel electrophoresis. 
 
4.3.1. Agarose gel electrophoresis 
Agarose gel electrophoresis is a suitable analytical method for separating DNA 
fragments of different sizes ranging from 100 bp to 25 kb. DNA fragments smaller than 100 bp 
are more effectively separated using polyacrylamide gel electrophoresis. DNA is loaded into 
pre-cast wells in the gel and electric current applied. Due to the phosphate backbone of the 
DNA (and RNA) molecule is negatively charged, thus DNA fragments will migrate toward the 
positively charged anode.  
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In this work, the catalytic activity of the nucleases in the DNA cleavage experiments 
was monitored by 1% (m/V) agarose gel electrophoresis. The DNA was visualized by ethidium 
bromide. Electrophoresis was performed in TAE buffer consisting of 40 mM Tris, 20 mM acetic 
acid, and 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0, using Bio-Rad Wide Mini 
Sub CellVR GT at 7 V/cm. Gene Ruler 1kb Plus DNA Ladder (Thermo Scientific) or Lambda 
DNA/EcoRI marker (Thermo Scientific) was applied for comparison as shown in Figure 4.8. 
 
 
Figure 4.8. Agarose gel electrophoresis picture of a, Lambda DNA/EcoRI Marker and b, 
GeneRuler 1 kb Plus DNA Ladder (https://www.thermofisher.com/). 
 
4.4. Synthesis and characterization of the water-soluble lipopolymer 
This work was done in collaboration with Interdisciplinary Excellence Centre, 
Department of Physical Chemistry and Materials Science,  and MTA-SZTE Biomimetic 
Systems Research Group, Department of Medical Chemistry, Faculty of Medicine (University 
of Szeged). 
 
4.4.1. Synthesis and purification of the water-soluble lipopolymer 
The applied materials were: Poly(ethyleneimine) (PEI, 30% (m/V) in water was 
purchased from Tokyo Chemicals), trimethylamine ((C2H5)3N, 99%), methylene chloride 
(CH2Cl2, anhydrous, ≥99.8%), cholesteryl chloroformate (C28H45ClO2, 95%), diethyl ether 
((CH3CH2)2O, anhydrous, ≥ 99.7%) were purchased from Sigma and acetone (CH3COCH3, ≥ 
99%) was manufactured by Molar. The synthesis and the purification of WSLP were carried 
out based on the description in the literature [133]. Briefly: 3 g of PEI (10 mL PEI solution) 
was mixed with 10 mL ice-cold methylene chloride and 100 µL trimethylamine. Then 1 g of 
cholesteryl chloroformate was added to 5 mL chilled methylene chloride and this solution was 
slowly mixed with the PEI solution. The mixture was stirred at 0 °C using 800 rpm for 12 h 
a b
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resulting in a pale yellow solid product. First, the product was completely dried by rotary 
evaporation (IKA, RV 3 evaporator) then the powder was dissolved into 50 mL of 0.1 M HCl 
and extraction using 50 mL methylene chloride was repeated three times. For the removal of 
the large aggregates, vacuum filtration was applied by standard P3 glass and paper filters with 
16-40 µm and 3-5 µm pore size, respectively. The filtered liquid was concentrated by rotary 
evaporation (50 °C, 2 h) then the WSLP was precipitated by acetone and the filtration was 
repeated as described above. Finally, the solid WSLP has been obtained by freeze drying (Christ 
Alpha, 1 2 LD dryer) for 1 day.  
 
4.4.2. Particle charge detection 
 The charge of the initial PEI and the synthesized WSLP was determined at pH = 7.4 
using a PCD-04 type of Mütek Particle Charge Detector. Namely, 10 mL of 0.01 M sodium 
dodecyl sulfate (SDS) solution in the PCD cell was titrated separately with 25.2 mL of 0.3 mg 
L–1 PEI and 26 mL of 0.6085 mg L–1 WSLP in 300 and 1000 µL steps, respectively. The 
streaming potential was recorded 30 s after each step. The measurements were analyzed and 
the charge neutralization point was appointed based on the sigmoidal shape of the charge 
titration curve. The possible extent of the PEI protonation, the cholesteryl substitution, and the 
presumable molecular weight of the synthesized WSLP were also calculated. 
 
4.5. Characterization of WSLP/pDNA complexes 
After WSLP was synthesized, plasmid DNA (pDNA) was mixed with it at different 
ratios to obtain WSLP/pDNA complexes. Condensation of the pDNA into WSLP was detected 
by agarose gel electrophoresis. The size, zeta potential, and morphological properties of free 
WSLP and WSLP/pDNA were studied by the following methods. 
 
4.5.1. Dynamic light scattering 
Dynamic light scattering (DLS) is a physical technique that can be used to detect the 
size distribution of polymers in solution or suspension of small particles [134]. DLS can be 
used for emulsions, micelles, polymers, proteins, nanoparticles or colloids. The basic principle 
is simply based on that the sample is illuminated by a laser beam and the fluctuations of the 
scattered light are determined at a known scattering angle θ by a fast photon detector. 
In this study, the hydrodynamic diameter and the ζ-potential of the WSLP itself and the 
WSLP/pDNA complexes were determined by dynamic and static light scattering (DLS and 
SLS, respectively) using a Malvern Zetasizer Nano ZS ZEN 4003 apparatus equipped with a 
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He-Ne laser (λ = 633 nm) at 25 ± 0.1 °C. The refractive index gradient was obtained by a 
Mettler Toledo Excellence RM50 refractometer. 
The average molecular weight of the initial PEI was determined by DLS measurements 
based on the Debye plot (KC/R as a function of the C concentration) using the Zimm equation 
(Equation 4.7). The slope of the fitting provided the second virial coefficient (2A2) and the 
intercept yielded the reciprocal of the molecular weight (1/Mw). 
𝐾𝐶
𝑅
=
1
𝑀𝑤𝑃
+ 2𝐴2𝐶       (4.7) 
Where K is a constant depending on the sample dn/dc, c is the sample concentration in g mL-1, 
R is the Rayleigh ratio (the ratio of scattered light intensity to incident light intensity). P is an 
angular dependent term (by default, assumed to be 1 for small molecules < 15 nm radius). 
4.5.2. Electron microscopy 
Scanning electron microscope (SEM), utilizes focused electron beam of low energy for 
studying the surfaces of solid objects. Electrons in the electron gun are released from the 
cathode and accelerated to the energy 1 – 50 keV by the anode. The electron beam is 
compressed by the condenser lenses (one or two). The magnetic field, created by the scan coils 
deflects the electron beam back and forth. The electron beam, centered by the objective lens to 
very fine spot (1-5 nm), scans the surface of the sample in a raster pattern. Primary electrons 
interact with the sample surface atoms, causing emissions of the secondary electrons that are 
determined, producing the image (Figure 4.9 a). The backscattered electrons are used to 
contrast the sample parts with different chemical compositions. In this work, the scanning 
electron microscopy (SEM) images were recorded by a Hitachi S-4700 Field Emission 
Scanning Electron Microscope using 20 kV accelerating voltage. 
 
 
Figure 4.9. A schematic diagram of a, scanning electron microscope (SEM) [135] and b, 
transmission electron microscope (TEM) [136]. 
a b
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Transmission electron microscopy (TEM) is a technique in which a beam of electrons 
is transmitted through a specimen to generate an image. The specimen is most often an ultrathin 
section less than 100 nm thick or a suspension on a grid. An image is produced from the 
interaction of the electrons with the sample as the beam is transmitted through the specimen. 
The basic principle is analogous to that of a light microscope but electron beams are used 
instead of light beams. The electrons are produced in an electron gun composed of a filament, 
an anode, and a Wehnelt cap1. The filament acts as a hot cathode in which a wire flows electric 
current and sets the electrons free. Those electrons are accelerated by a high potential (~100 
kV). Lenses act as a coil device focusing the beam in order to obtain the magnification of the 
image and examine sensitive details on the nanoscale. All this happens in a vacuum to avoid 
collisions with the air molecules. TEM is equipped with a camera through which the transmitted 
beam passes and generates the image. A fluorescent screen is used to adjust the electron path 
through TEM and to perform a rough search for the sample structures (Figure 4.9 b). A Jeol 
JEM-1400plus equipment (Japan) with 120 keV accelerating voltage was applied and the 
samples were dropped on the surface of formvar-coated grid. The pictures were analyzed by 
ImageJ software. 
 
4.6. Experiments with cancer cell lines 
The experiments performed to detect the cytotoxicity, biocompatibility, and transfection 
efficiency of the water-soluble lipopolymer and the various plasmids were carried out in 
collaboration with the Department of Biochemistry and Molecular Biology. 
 
4.6.1. Cell culture materials 
A549 human lung cancer cells and HeLa cervical adenocarcinoma cells were obtained 
from the American Type Culture Collection (ATCC, USA). Cells were maintained in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), L-glutamine (2 mM) (all purchased from Lonza), penicillin (100 IU/mL) and 
streptomycin (50 μg/mL) (SERVA) in a humidified atmosphere containing 5% CO2 at 37°C. 
The stock solutions were freshly prepared using MQ (Millipore, Milli-Q Integral3) ultrapure 
water (18.2 MΩ·cm at 25 °C) in every case. The pEGFP-N3 and the pSpCas9(BB)-2A-GFP 
(pX458) plasmids were purchased from Addgene (see detailed information in Appendix A.2, 
A.3. The Qiagen Plasmid Mini Kit was purchased from Qiagen. 
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 The MTT reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was 
obtained from SERVA. LipofectamineTM 3000 transfection reagent was obtained from Thermo 
Fisher Scientific. 
4.6.2. MTT assay 
The MTT assay is a sensitive, accurate, and quantitative colorimetric assay that detects 
viability, proliferation, and activation of cells [137]. The assay depends on the ability of 
mitochondrial dehydrogenase enzymes in viable cells to convert the yellow water-soluble 
substrate 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl tetrazolium bromide (MTT) into purple 
formazan crystals that are insoluble in water (Figure 4.10) [138]. 
 
Figure 4.10. Conversion of MTT to formazan by NADH-dependent reductases. 
 
The insoluble formazan crystals are solubilized and the resulting color intensity is 
quantified by measuring absorbance in the range of 500-600 nm by using a multi-well 
spectrophotometer. The darker the solution, the greater the number of viable and metabolically 
active cells. 
In this work, the cytotoxicity of WSLP/pDNA complexes prepared according to the 
mass and N/P ratios was investigated by MTT assay. A549 and HeLa cells were seeded at 5000 
cells/well density in 96-well plates and incubated for 24 h at 37 °C to reach 70% confluence. 
Then the medium was removed and the WSLP, WSLP/pDNA complexes were added to the 
cells in serum-free DMEM. Following the incubation at 37 °C for 24 h and 48 h, the medium 
was removed and the cells were washed with phosphate buffered saline (1×PBS, pH 7.4). Cell 
viability was assessed by adding the MTT reagent prepared in serum free DMEM to a final 
concentration of 0.5 mg mL–1. After incubation (1 h at 37 °C), the media was removed and 100 
μL DMSO (Serva Electrophoresis GmbH) was added to dissolve the formazan crystals. The 
absorbance was measured at 570 nm using Synergy HTX plate reader (BioTek). Data were 
analyzed by GraphPad Prism 7 software (GraphPad Software), where untreated cells served as 
the control. 
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4.6.3. Internalization of plasmid DNA into the cancer cells 
Transfection is a process by which nucleic acids are deliberately introduced into 
eukaryotic cells. Transfection can be carried out using different delivery systems mentioned 
previously in section 2.4. During our work commonly A549 and HeLa cells were seeded in 6-
well tissue culture plates at a density of 2×105 cells per well in 10% FBS-containing DMEM 
and were left to grow. After the cells reached 70% confluency, the medium was replaced with 
serum-free DMEM and the cells were transfected with WSLP/pDNA complexes at DNA 
concentration of 2.5 μg per well. After 24 h incubation at 37°C, the medium was replaced by a 
DMEM medium supplemented with 10% FBS, L-glutamine, penicillin, and streptomycin in 
concentrations described above. The cells were incubated for an additional 48 h, then were 
trypsinized, washed, and resuspended in PBS. The transfection efficiency was detected by flow 
cytometry using FACSCalibur™ platform via quantification of EGFP fluorescence. The 
analysis of the FACS data was performed with Flow Jo and Graphpad softwares. 
 
4.6.4. Fluorescence microscopy 
A fluorescence microscope can selectively detect the distribution of fluorescent 
molecules [139]. The image acquisition process with the fluorescence microscope is shown in 
Figure 4.11. The light from the source passes through the excitation filter, to select the 
appropriate range of wavelengths. The dichroic mirror focuses the light on the specimen. The 
light absorbed by the fluorophores allows them to emit a lower-energy radiation. The emitted 
light passes through the dichroic mirror and the emission filter to reach the detector [140]. 
 
Figure 4.11. The scheme of the fluorescence microscope [141]. 
 
The samples can be expressed fluorescent proteins or molecules labelled with 
fluorescent stains. Hoechst blue fluorescent dyes are supravital minor groove–binding DNA 
stains with AT selectivity (Figure 4.12) [142]. 
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Figure 4.12. Structure of Hoechst dyes (from Handbooks of Invitrogen detection technologies). 
 
We have assessed the transfection process by fluorescence microscopy as well. For this 
A549 cells were seeded on glass coverslips (VWR) placed into the wells of a 24-well plate and 
were left to grow. When the cells reached about 70% confluency, the culture medium was 
replaced to serum-free DMEM and the cells were transfected with WSLP/pEGFP-N3 and with 
PEI/pEGFP-N3 complexes at 10/1 N/P ratio with DNA concentration of 0.75 μg per well. After 
24 h the cells were washed with PBS and were left to grow for 48 hours in FBS-containing 
culture medium. Cells were visualized by OLYMPUS BX51 fluorescence microscope and the 
photos were taken by Olympus DP70 camera (Olympus, Tokyo, Japan) with or without staining 
with 3.25 μM Hoechst 33342 (Sigma-Aldrich) dye for 30 minutes. 
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5. RESULTS AND DISCUSSION 
 
5.1 Design of a new DNA construct for affinity based purification of ΔN4-NColE7 
The computer design of artificial nucleases relies on precise reproduction of the 
designed sequence during the synthesis of the protein. However, production of such proteins in 
high yield and purity is usually difficult and requires multistep chromatographic methods often 
leading to a significant loss of target proteins. Therefore, it is a topical issue to develop 
purification procedures for the designed and similarly, for the native proteins with precisely 
determined sequences [143-147]. 
Affinity chromatography is a popular approach, allowing for easy protein purification. 
The affinity tag may be a short amino acid sequence or a protein fused to either the C- or N-
terminus of the target recombinant protein. Such tags facilitate the purification and detection of 
the target protein, and are removed by a specific protease after the purification procedure. 
Unfortunately, the tag removal is not always a straightforward procedure. 
The search for ideal affinity tags and tag-removal methods is necessitated in protein 
chemistry as exemplified by recent reviews [148-158]. Various methods have been elaborated 
to cleave and remove the affinity tags after getting rid of impurities. Specific protein-based 
cleavage enzymes, however, display several disadvantages for example, shorter or longer 
amino acids strings will remain at the termini of the purified protein after the enzymatic 
cleavage. These may disturb the folding and/or the function of the target protein. To avoid such 
consequences, we have modified an existing protein expression vector: pET-21a. The C-
terminal 6×His affinity tag can be completely removed from the proteins purified from this new 
DNA construct. The new DNA vector is an advantageous tool for protein purification, when 
the complete removal of the affinity (or other) tags, without any remaining amino acid residue 
is essential. 
 
5.1.1. Construction of the new cloning site into the pET-21a (AmpR) DNA vector 
BsmBI (Esp3I) restriction endonuclease recognizes 5’-gagacg-3’ DNA sequence and 
cleaves the DNA outside the recognition region. Including such restriction site in the cloning 
region of a plasmid provides an opportunity to eliminate this recognition sequence during the 
insertion of a gene into the DNA carrier. For this reason, we redesigned the cloning site of the 
pET-21a plasmid (Novagen) as it is schematically depicted in Figure 5.1. This construct allows 
to insert the target gene precisely between the 5’-atg-3’ start codon included in the NdeI 
recognition site, and the SRHS code which will serve the removal of the affinity tag.  
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Figure 5.1. Schematic representation of pET-21a*-SRHS plasmid with the redesigned cloning 
site.  
 
The original pET-21a sequence contains two additional BsmBI restriction sites as shown 
in (Figure 5.2 a), so first, the knockout of these restriction sites was necessary. Both sites were 
knocked out using a modified QuikChange protocol (QCM, Stratagene). We used KOD-FX-
DNA polymerase in PCR, because this enzyme precisely amplifies long DNA sequences. The 
following primers were applied for the knockout modifications: BsmBI-1F 5’- 
gtcactggtgaaaagaaaaaccacc-3’; BsmBI-1R 5’-acgggcaacagctgattgcc-3’ and BsmBI-2F 5’-
gacggtcacagcttgtctgtaag-3’; BsmBI-2R 5’-accgggagctgcatgtgtca-3’. The success of 
modifications was checked by the sequencing reactions with the designed Seq-BsmBI-1F: 5’-
aatgcgcgccattaccga-3 or Seq-BsmBI-2F: 5’-ggcatcagtgaccaaacag-3’ primers. One of these 
BsmBI sites was located within the ampicillin resistance gene (Figure 5.2 a), so the mutation 
of one base pair within the restriction site had to be carried out without affecting the ampicillin 
resistance gene properties. The success of this procedure was verified by transformation of 
bacterial cells, and subsequently growing them on LB(Amp+) plates.  
A specific double-strand oligonucleotide was designed and inserted into the new cloning 
site using the original NdeI and SalI restriction enzymes. This sequence contains the two new 
BsmBI sites for cloning the target gene into the mutated pET-21a. This is followed by a 
sequence encoding for SRHX, where X can be any amino acid and it is encoded by the nnn 
codon in the DNA sequence. 
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a 
gtgaaaccagtaacgttatacgatgtcgcagagtatgccggtgtctcttatcagaccgtttcccgcgtggtgaaccaggccagccacgtttctg
cgaaaacgcgggaaaaagtggaagcggcgatggcggagctgaattacattcccaaccgcgtggcacaacaactggcgggcaaacagtcgttgct
gattggcgttgccacctccagtctggccctgcacgcgccgtcgcaaattgtcgcggcgattaaatctcgcgccgatcaactgggtgccagcgtg
gtggtgtcgatggtagaacgaagcggcgtcgaagcctgtaaagcggcggtgcacaatcttctcgcgcaacgcgtcagtgggctgatcattaact
atccgctggatgaccaggatgccattgctgtggaagctgcctgcactaatgttccggcgttatttcttgatgtctctgaccagacacccatcaa
cagtattattttctcccatgaagacggtacgcgactgggcgtggagcatctggtcgcattgggtcaccagcaaatcgcgctgttagcgggccca
ttaagttctgtctcggcgcgtctgcgtctggctggctggcataaatatctcactcgcaatcaaattcagccgatagcggaacgggaaggcgact
ggagtgccatgtccggttttcaacaaaccatgcaaatgctgaatgagggcatcgttcccactgcgatgctggttgccaacgatcagatggcgct
gggcgcaatgcgcgccattaccgagtccgggctgcgcgttggtgcggatatctcggtagtgggatacgacgataccgaagacagctcatgttat
atcccgccgttaaccaccatcaaacaggattttcgcctgctggggcaaaccagcgtggaccgcttgctgcaactctctcagggccaggcggtga
agggcaatcagctgttgcccgtctcactggtgaaaagaaaaaccaccctggcgcccaatacgcaaaccgcctctccccgcgcgttggccgattc
attaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgtaagttagctcactcattaggcaccggg
atctcgaccgatgcccttgagagccttcaacccagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttc
tttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgt
cgcttgcggtattcggaatcttgcacgccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgc
cggcatggcggccccacgggtgcgcatgatcgtgctcctgtcgttgaggacccggctaggctggcggggttgccttactggttagcagaatgaa
tcaccgatacgcgagcgaacgtgaagcgactgctgctgcaaaacgtctgcgacctgagcaacaacatgaatggtcttcggtttccgtgtttcgt
aaagtctggaaacgcggaagtcagcgccctgcaccattatgttccggatctgcatcgcaggatgctgctggctaccctgtggaacacctacatc
tgtattaacgaagcgctggcattgaccctgagtgatttttctctggtcccgccgcatccataccgccagttgtttaccctcacaacgttccagt
aaccgggcatgttcatcatcagtaacccgtatcgtgagcatcctctctcgtttcatcggtatcattacccccatgaacagaaatcccccttaca
cggaggcatcagtgaccaaacaggaaaaaaccgcccttaacatggcccgctttatcagaagccagacattaacgcttctggagaaactcaacga
gctggacgcggatgaacaggcagacatctgtgaatcgcttcacgaccacgctgatgagctttaccgcagctgcctcgcgcgtttcggtgatgac
ggtgaaaacctctgacacatgcagctcccggagacggtcacagcttgtctgtaag 
 
 
Figure 5.2. Construction of pET-21a*-SRHS plasmid. a, Part of the pET-21a vector with the 
two highlighted BsmBI sites (red background) in the original sequence. The ampicillin 
resistance gene is highlighted by green background, while the designed sequencing primers to 
check the success of BsmBI knockout experiments are denoted by bold italic. b, The sequence 
of the double-strand oligonucleotide used to establish the new cloning site in the carrier DNA. 
The redesigned cloning site includes all the restriction enzyme recognition sites of the pET-21a 
vector and two additionally inserted BsmBI recognition sites (the arrows pointing downwards 
show the BsmBI cleavages outside the recognition sites). Cloning the gene of the target protein 
between the two BsmBI sites allows the expression from the atg start codon (underlined) within 
the NdeI restriction site.  
5’-tatgGAGACGggatccCGTCTCtccaggcacnnngaattcgagctcg-3’
3’- acCTCTGCcctaggGCAGAGaggtccgtgnnncttaagctcgagcagct-5’
b
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Thus, by cloning this designed DNA sequence into the BsmBI knockout pET-21a 
plasmid, we have got a library of new plasmids, from which we isolated those containing the 
codes of SRHS and SRHH amino acids sequences. As it is well-known from the literature, the 
SRHX protein sequences can be hydrolyzed at the N-terminus of this site using Ni(II) ions 
[160]. Therefore, the SRHX sequence serves as the hidden stop codon, which is activated only 
in its translated form and ideally after the protein purification procedure. The SRHS sequence 
is followed by the hexahistidine code through a linker sequence containing the restriction 
enzyme recognition sites of the original pET-21a vector (Figure 5.2 b). The modified plasmid 
with SRHS selected for the further experiments, was denoted as pET-21a*-SRHS. The SRHS 
sequence within the expressed protein from this new DNA construct can be cleaved by Ni(II) 
and thus, the C-terminal fusion sequence including the 6×His-tag can be removed. 
 
5.1.2 Expression and purification of ΔN4-NColE7-6×His by nickel-affinity resin 
To verify the suitability of the new plasmid for the purpose of protein purification 
without any remaining amino acid sequence, first, we started with a well studied protein in our 
laboratory, which is the ΔN4-NColE7 protein – the nuclease domain of Colicin E7 bacterial 
toxin lacking four N-terminal amino acids. The template plasmid pQE70-NColE7/Im7 [159] 
was kindly provided by prof. Kin-Fu Chak (Institute of Biochemistry, National Yang-Ming 
University, Taipei, Taiwan, Republic of China). The DNA segment, encoding the ΔN4-NColE7 
sequence was modified to include BsmBI restriction site at its termini by PCR using the 
following oligonucleotide primers: 
B-DN4 – forward: 5′-attcgtctccatatgccagggaaggcaa-3′ and  
B-ColC – reverse: 5′-attcgtctccctggatttacctcggtgaatatcaatatg-3′. 
Both the pET-21a*-SRHS plasmid and the PCR product were digested by BsmBI 
restriction endonuclease (Figure 5.3 a). The ligated pET-21a*-ΔN4-NColE7-SRHS plasmid 
was applied to transform competent DH5α E. coli cells for DNA amplification. Several colonies 
were selected and cultured in separate LB (amp+) solutions for plasmid purification. The 
resulted new plasmids should contain the target sequence between the NdeI restriction site and 
SRHS sequence. We have checked this by BamHI cleavage. This restriction enzyme site is 
inserted between the to BsmBI restriction site, and therefore, it is also eliminated upon 
successful cloning. Finally, the DNA sequencing proved the precise ligation.  
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Figure 5.3. a) Scheme of the gene cloning technology by using the new plasmid. The target 
gene is amplified by PCR, then both the plasmid and the target genes were digested by BsmBI 
at 37 °C for two hours. The DNA fragments were ligated by T4 ligase to form the recombinant 
DNA. b) SDS PAGE analysis of the batch Ni(II)-affinity purification procedure. Lane 2: 20 μl 
aliquot of the total protein fraction obtained after resuspending the pellet in 10 mL 1×binding 
buffer. Lane 3: 20 μl aliquot of the soluble protein fraction, i.e., from the supernatant after the 
centrifugation of total protein fraction. Lane 4: 20 μl aliquot of the supernatant after binding to 
the Ni-NTA resin. Lane 5 (Wash1): 1 μl aliquot of the resin after washing with 4×2 bed volume 
wash buffer (20 mM Tris pH 7.9; 60 mM Imidazole; 500 mM NaCl; 0.1% Triton X-100. Lane 
6 (Wash2): 1 μl aliquot of the resin after washing with 2×2 bed volume wash buffer with an 
increased imidazole concentration of 100 mM. Lane 7 (Wash3): 1 μl aliquot of the resin after 
washing with 2×2 bed volume of 100 mM pH 8.2 HEPES buffer. 
 
The ΔN4-NColE7-6×His protein was expressed in BL21 (DE3) E. coli cells using the 
pET-21a*-ΔN4-NColE7-SRHS plasmid and then purified by batch type nickel-affinity 
chromatography by using a Novagen His•Bind® resin as described in the experimental section. 
ΔN4-NColE7-6×His protein was separated from other bacterial proteins by its specific binding 
to the resin through the 6×His affinity tag. The success of protein expression and purification 
was analyzed by SDS-PAGE (Figure 5.3 b). The overexpressed target protein could 
quantitatively be solubilized in the binding buffer as shown in lane 3. The binding efficiency of 
the 6×His-tag was demonstrated by the lack of the target protein in the supernatant (lane 4) 
solution after the treatment with the nickel-affinity resin. Wash buffer (500 mM NaCl, 20 mM 
Tris-HCl pH 7.9) containing 60 mM imidazole was used to remove all the impurities from the 
resin and a clear band on the gel close to 20 kDa size marker band was assigned to the ΔN4-
NColE7-6×His protein – calculated molecular weight is 17220 Da. The 6×His tag was removed 
from the C-terminus of this protein by Ni(II)-induced cleavage reaction, set up directly on the 
protein-loaded resin. The details of the Ni(II)-induced cleavage are parts of another Ph.D. topic.  
ba
49 
 
This purification strategy provided the metalloprotein with a native protein sequence, 
avoiding any remnant amino acid residues after the removal of the affinity tag, while 
overcoming several above listed disadvantages of the proteases. This one-step purification 
method by using the new plasmid resulted in ΔN4-NColE7 protein samples of high purity with 
an average yield of ∼3.0 mg protein from 1 L culture (∼4.0 g of wet cells). This yield is higher 
compared to the previous purification method in our lab, which was 2.5 mg per liter of culture 
most probably because the toxicity of ΔN4-NColE7 protein was decreased by the C-terminal 
6×His tag.  
 The new DNA construct designed by us, can be used with various tags at the C-terminus 
for affinity chromatographic applications. As a result of the protein expression from this vector, 
a C-terminal hexahistidine peptide tag is fused to the target protein [160]. The cytotoxicity of 
ΔN4-NColE7, attributed to the non-specific DNA cleavage within the cells during the protein 
expression, was decreased by using the C-terminal 6×His tag. Furthermore, it was found that 
the new vector could also carry the gene of NColE7 and R447G-NColE7 (KGNK) mutant 
successfully in DH5 bacterial cells, while this was not possible with the original pET-21a 
vector without the simultaneous cloning of the gene of the inhibitory protein Im7 [157,161]. I 
will discuss these experiments in the following chapter.  
 
  
50 
 
5.2 Modulation of the catalytic activity of NColE7 by the 6×His tag 
The oligohistidine sequence in the C-terminal affinity tag introduced by the new protein 
expression DNA construct described in the previous chapter, may modulate the nuclease 
activity of the nuclease domain of the Colicin E7 metalloprotein (NColE7) via both non-specific 
and coordinative interactions. This highlights the possibility of tailoring the properties of a 
selected metalloprotein by applying an oligohistidine fusion sequence. To investigate this 
phenomenon we have synthesized the genes of the NColE7-6×His protein (Scheme 5.1) and its 
selected mutants and whenever it was possible, we also purified the protein, for further 
characterization of its solution structure, metal ion-binding and catalytic activity. 
 
 
 
Scheme 5.1. Scheme of the amino acid sequence of the NColE7-6×His protein. The arginine 
(R447) amino acid highlighted by the grey background close to the N-terminus was mutated to 
G (R447G mutation) in the KGNK-6×His protein. H544, H569 and H573 metal ion-binding 
histidines are underlined in the HNH motif (red characters), and the general base H545 histidine 
is underlined and also highlighted by the grey background. The fusion sequence is in italic, in 
which the SRHS nickel(II)-sensitive motif and the hexahistidine function is underlined. The 
numbering of the amino acids is based on the original Colicin E7 amino acid sequence.  
 
5.2.1. DNA cloning and cytotoxicity experiments reflecting the catalytic activity of the 
nucleases 
The NColE7 protein is highly cytotoxic due to the non-specific DNA cleavage within 
the bacterial cells. The minor leakage of the protein expression prevents even the gene cloning 
procedure in pET-21a without the parallel expression of the inhibitory protein. pET-21a*-
NColE7-SRHS and pET-21a*-KGNK-SRHS plasmids were constructed similarly such as pET-
21a*-ΔN4-NColE7-SRHS by using the pET-21a-NColE7/Im7 plasmid containing the genes of 
NColE7 and the Im7 immunity proteins, as a template to amplify NColE7 and KGNK genes. 
The B-ColNNN, forward (5′-attcgtctccatatgaaacggaataagccag-3′) and B-ColC reverse 
(5′-attcgtctccctggatttacctcggtgaatatcaatatg-3′) oligonucleotide primers were used for NColE7 
amplification and the B-KGNK-N* forward primer (5′-attcgtctccatatgaaacggaataagccag-3′) 
instead of B-ColNNN for KGNK (the explanation of the protein sequences is shown in Scheme 
5.1. 
After inserting the genes of NColE7 and KGNK proteins into the pET-21a*-SRHS 
vector and transforming the bacterial cells, bacterial colonies appeared on the LB(amp+) agar 
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plates. This suggests that the modified 6×His-tagged proteins show decreased catalytic activity 
compared to those with native sequences. However, the absence of the Im7 gene during the 
cloning procedure enhances the selection of plasmids including erroneous genes, which results 
in expressing non-toxic proteins. Therefore, we have checked the nucleotide sequences of the 
cloned genes in randomly selected bacterial colonies. Among these, we could indeed identify 
the pET-21a*-NColE7-SRHS plasmid with the error-free gene, coding the expected NColE7-
6×His protein, and thus, supporting the decreased catalytic activity of the tagged protein. 
Nevertheless, the sequencing experiments also revealed several pET-21a*-NColE7-SRHS 
plasmid preparations containing wrong, randomly mutated NColE7 genes, from which 
modified proteins with decreased or no toxicity could be expressed. The NColE7 nuclease 
sequence suffered from either random point mutations or random mutations causing reading 
frame shifts (Table 5.1). It is worth mentioning that some of the mutations occurred at the same 
locations as detected in a previous article [79], such as the point mutation at D557 or frameshift 
at …IDIHRGK… sequence, the latter mutation affecting the H573 residue, essential for the 
metal ion binding. Ont he other hand, the sequences of the verified pET-21a*-KGNK-SRHS 
plasmids were in agreement with the expected sequence. Thus, the cytotoxicity of the 
KGNK-6×His protein seems to be negligible compared to that of NColE7-6×His. 
 
Table 5.1. Mutations found in the gene of NColE7 in the DNA cloning experiments. 
 
Types of mutations   Mutation site 
Single point mutation S504L 
D557G 
Reading frame shift …IDIHRGK → …MIFTEVN… 
…PGKA… → …ATLStop 
…RKKFWE… → …VRNSGK… 
…FDDFR… → …LMILStop 
 
After the identification of the pET-21a*-NColE7-SRHS and pET-21a*-KGNK-SRHS 
plasmids containing the expected sequences, we have applied these DNA constructs for the 
transformation of various bacterial cells in order to check their toxic effect reflecting the 
catalytic activity of the expressed metallonucleases. In case of Mach1 and DH5 cells 
optimized for DNA cloning, we observed the appearance of bacterial colonies, although the 
bacterial growth was partially inhibited (Figure 5.4). Mach1 colonies were significantly smaller 
than the DH5 colonies using pET-21a*-NColE7-SRHS. The colony size of the Mach1 cells 
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transformed with pET-21a*-NColE7-SRHS was significantly smaller than that of the pET-
21a*-KGNK-SRHS containing cells. It is shown that the effect of the NColE7-6×His protein 
expression leakage is already lethal to BL21(DE3) cells, but bacterial colonies still appeared 
after the transformation experiments with pET-21a*-KGNK-SRHS 6×His plasmid. These 
results support that the catalytic activity of the 6×His tagged enzymes decreased in comparison 
with the native sequences. The slightly more pronounced protein expression leakage and/or 
sensitivity in Mach1 could even differentiate between the NColE7-6×His and KGNK-6×His 
sequences, in agreement with the higher activity of the former enzyme.  
 
Figure 5.4. Formation of bacterial colonies on the LB(amp+) agar plates. DH5 and Mach1 
cells are optimized for DNA cloning, while BL21(DE3) is a cell for protein expression.  
 
The Zn2+ ion in the active center of NColE7 has an essential role in the catalytic 
mechanism. The scissile phosphodiester group of the substrate can bind to the metal ion at the 
fourth coordination site, replacing the coordinated water molecule. Any additional histidine 
within the C-terminal tag can influence this event. To monitor the possible role of these 
histidines we have carried out mutation experiments. First, we changed the code of histidine 
within the SRHS sequence to the code of glutamine (Q) resulting in pET-21a*-NColE7-SRQS 
and pET-21a*-KGNK-SRQS plasmids. The sequencing results revealed that the mutation of 
histidine of SRHS was successful in both plasmids, but we could also detect random mutations 
in some of the pET-21a*-NColE7-SRQS plasmids. Thus, the cytotoxicity of these plasmids 
(through the minor protein expression) in Mach1 and DH5 cells did not show significant 
change as compared to the pET-21a*-NColE7-SRHS and pET-21a*-KGNK-SRHS plasmids. 
The hexahistidine tag is expected to inhibit the catalytic reaction when it binds to the 
catalytic Zn2+ ion. To verify this hypothesis, we modified the genes of the NColE7-SRQS and 
KGNK-SRQS proteins by inserting a designed short dsDNA sequence (NoHistag) using the 
XhoI restriction endonuclease site between the codes of the SRQS and 6×His motifs. This short 
dsDNA can be inserted in two different orientations during the ligation experiment. For this 
DH5 Mach1                                           BL21  
DNA                                           DNA Protein  
pET-21a*-
NColE7-SRHS 
pGEX-
6P-1
pGEX-6P-1
pET-
21a*-
KGNK
-SRHS 
pET-
21a*-
NColE7
-SRHS 
cells cells
pET-
21a*-
KGNK-
SRHS 
pET-
21a*-
NColE7
-SRHS 
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reason, it was designed to include a stop codon independently of the orientation. Thus, it 
prevents the expression of the 6×His sequence. Therefore, we expected an increased catalytic 
activity and cytotoxicity of the new plasmids. The two different proteins are expressed with C-
terminal linker sequences of different lengths (Scheme 5.2) without bearing strongly 
coordinating amino acid side-chains (His or Cys).  
 
 
 
Scheme 5.2. Top: The nucleotide sequence of the modified cloning region of pET-21a*-SRHS 
vector showing the mutations that led to SRHS → SRQS amino acid sequence modification, as 
well as the results (A and B) of the insertion of the NoHistag short dsDNA in two different 
orientations into the XhoI restriction enzyme recognition site. Note that the scored sequences 
after the newly established stop codons are not expressed. Information about the further 
restriction sites is also included in the scheme. Bottom: The sequences of the expressed 
NColE7-type proteins based on the DNA constructs above. The KGNK protein sequences can 
be read by exchanging the underlined R to G.  
 
In the transformation experiments we still obtained colonies, which were verified for 
the successful modifications of the plasmids. To this end, we inserted a unique AflII restriction 
endonuclease cleavage site (5'-cttaag-3') into the NoHistag dsDNA sequence, so that the 
NdeI BsmBI BamHI BsmBI EcoRI SacI XhoI 6x-His Stop
5’-catatggagacgggatcccgtctctccaggcactcggaattcgagctc....ctcgagcaccaccaccaccaccactga
M E T G S R L S R H S E F E L .... L E H H H H H H
 Ni(II) cleavage site
NdeI BsmBI BamHI BsmBI EcoRI SacI XhoI 6x-His Stop
5’-catatggagacgggatcccgtctctccaggcagtcggaattcgagctc....ctcgagcaccaccaccaccaccactga
M E T G S R L S R Q S E F E L .... L E H H H H H H
XhoI
5’-catatggagacgggatcccgtctctccaggcagtcggaattcgagctc....ctcgag
M  E  T  G  S  R  L  S  R  Q  S  E  F  E  L .... L  E 
NoHistag sequence
gaccttaaggcggccgcataactactcgagcaccaccaccaccaccac-3’
D L K A A A Stop  XhoI 6×His-tag
 XhoI
5’-catatggagacgggatcccgtctctccaggcagtcggaattcgagctc....ctcgag
M  E  T  G  S  R  L  S  R  Q  S  E  F  E  L .... L  E 
NoHistag sequence
tagttatgcggccgccttaaggtcctcgagcaccaccaccaccaccac-3’
Stop XhoI 6×His-tag
pET-21a*-SRHS
pET-21a*-SRQS
A
B
NColE7-6×His MKRNKPGKATGKGKPVNNKWLNNAGKDLGSPVPDRIANKLRDKEFKSFDDFRKKFWE
NColE7-SRQS-6×His MKRNKPGKATGKGKPVNNKWLNNAGKDLGSPVPDRIANKLRDKEFKSFDDFRKKFWE
NColE7-SRQS-NoHis-A MKRNKPGKATGKGKPVNNKWLNNAGKDLGSPVPDRIANKLRDKEFKSFDDFRKKFWE
NColE7-SRQS-NoHis-B MKRNKPGKATGKGKPVNNKWLNNAGKDLGSPVPDRIANKLRDKEFKSFDDFRKKFWE
EVSKDPELSKQFSRNNNDRMKVGKAPKTRTQDVSGKRTSFELHHEKPISQNGGVYDM
EVSKDPELSKQFSRNNNDRMKVGKAPKTRTQDVSGKRTSFELHHEKPISQNGGVYDM
EVSKDPELSKQFSRNNNDRMKVGKAPKTRTQDVSGKRTSFELHHEKPISQNGGVYDM
EVSKDPELSKQFSRNNNDRMKVGKAPKTRTQDVSGKRTSFELHHEKPISQNGGVYDM
DNISVVTPKRHIDIHRGKSRHSEFELVDKLAAALEHHHHHH
DNISVVTPKRHIDIHRGKSRQSEFELVDKLAAALEHHHHHH
DNISVVTPKRHIDIHRGKSRQSEFELVDKLAAALEDLKAAA 
DNISVVTPKRHIDIHRGKSRQSEFELVDKLAAALE
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successfully ligated oligonucleotide plasmid constructs could be cleaved by this enzyme. The 
plasmid digestion experiments by AflII revealed more than 50% success of the insertion of the 
oligonucleotide. The modified plasmids were subjected to sequencing. 
We expected an increased catalytic activity and cytotoxicity of the new plasmids, able 
coding for proteins with less coordinating histidine side-chains in the C-terminal tag. Figure 
5.5 shows the comparison of the effect of pET-21a*-Nucl-SRHS, pET-21a*-Nucl-SRQS and 
pET-21a*-Nucl-SRQS-NoHistag plasmids (where Nucl is either NColE7 or KGNK) on the 
bacterial colony formation with BL21 cells optimized for protein expression. All the NColE7 
containing plasmids killed the cells, but for all KGNK plasmids colony formation was observed. 
The inhibitory effect could still be observed, which decreased the toxicity to an extent that is 
enough for protein-expressing bacteria harboring the KGNK-type plasmids to survive, but not 
for those transformed by the more active NColE7-type plasmids.  
 
 
 
Figure 5.5. Inhibition effect of pET-21a*-Nucl-SRHS, pET-21a*-Nucl-SRQS and pET-21a*-
Nucl-SRQS-NoHistag plasmids (where Nucl is NColE7 – left – or KGNK – right) on 
BL21(DE3) bacterial colony formation with and without His affinity tag. There is no colony 
formation when Nucl = NColE7, but a few bacterial colonies appeared when Nucl = KGNK. 
 
This result suggests that the C-terminal tag (even without bearing strongly coordinating 
amino acid residues) can decrease the catalytic activity of KGNK through a non-specific steric 
effect, likely involving non-covalent interactions with the active site. Thus, inhibition most 
probably occurs through a complex mechanism, involving the combination of the steric and 
coordinative effects. We purified the KGNK-6×His protein as described in the experimental 
section for more detailed in vitro catalytic investigation to learn more about the effect of His-
tag on the enzyme function.  
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5.2.2. Purification and characterization of KGNK-6×His protein 
The KGNK-6×His protein fractions were analysed by SDS-PAGE (Figure 5.6). The 
soluble protein fraction contains the overexpressed target protein at around ~ 20 kDa (lane 2). 
The calculated average molecular mass is 17779.03 Da. The binding efficiency of the 6×His-
tagged protein to the nickel-loaded IMAC resin was indicated by the absence of the target 
protein in the supernatant (lane 4) following the treatment of the protein solution with the resin.  
 
 
Figure 5.6. The SDS PAGE analysis of the batch Ni(II)-affinity purification of the KGNK-
6×His protein is visualized on the gel photo above. Lane 1: protein marker. Lane 2: 20 μL 
sample of the supernatant after the sonication and centrifugation of the resuspended cells. Lane 
3: 20 μL sample obtained after sonicating, centrifuging of the cells and resuspending the pellet 
in 5 mL of 1×binding buffer – this fraction represents the insoluble protein fraction lacking the 
target protein. Lane 4: 20 μL aliquot of the supernatant after mixing the soluble protein fraction 
with the Ni-NTA resin and centrifugation. Lane 5: 0.38 μL aliquot of the resin after washing 
with 5×2 bed volume of wash buffer (20 mM Tris pH 7.9; 60 mM imidazole; 500 mM NaCl). 
Lane 6: 0.3 μl aliquot of the protein eluted from the resin by elution buffer (20 mM Tris-HCl, 
pH 7.9, 0.5 M NaCl, 1 M imidazole). Lane 7: 1 μL aliquot of the resin after the protein elution. 
Lane 8: 0.23 μL aliquot of the protein solution after buffer exchange. 
 
All the impurities were removed from the resin by subsequent washing steps, and a clear 
band on the gel was assigned to the KGNK-6×His protein (lane 5). The protein was eluted from 
the resin by the elution buffer (lane 6) and then it was buffer-exchanged with 20 mM HEPES 
pH 7.7 prior to catalytic experiments.  
It is worth mentioning that the yield of the pure KGNK-6×His protein was ∼ 0.3 mg 
from 1 L culture, i.e. from ∼ 4.0 g of wet cells which is at least 10 times less than the yield we 
could achieve with e.g. the ΔN4-NColE7-6×His protein previously. This reflects that the 6×His 
attachment couldn’t completely inhibit the nuclease activity of the KGNK protein and the 
expressed protein is slightly toxic to the cells. 
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CD spectroscopy was applied to monitor the protein folding after purification and to 
estimate the fractions of secondary structure elements. Evaluation of the CD spectrum of the 
KGNK-6×His protein by the BeStSel software [162] revealed that the relative α-helical content 
is ~14% (Figure 5.7). As expected, this is slightly less than the α-helical content of the Zn2+-
loaded KGNK protein calculated by BeStSel: ~16% [73,144]. The reason for this is that KGNK-
6×His is longer by 16 amino acids due to its C-terminal fusion tag, displaying most probably 
non-helical structure. This result suggests that the protein is in its functionally folded form. 
 
 
 
Figure 5.7. Fitting of the far UV CD spectra of the KGNK-6×His protein between 190 and 250 
nm to determine the secondary structure fractions by the BeStSel program. The result of the 
secondary structure estimation is shown in the inset. 
 
 ICP-MS measurements with the same batch of the purified KGNK-6×His revealed that 
the protein was obtained in its Zn2+-loaded form containing approximately one equivalent of 
metal ion (36.99 μM Zn2+ for 30 μM protein). The Zn2+ ions in NColE7 and NColE9 are bound 
extremely tightly in the HNH catalytic center, characterized by an apparent dissociation 
constant Kd ~ 10
–9 value [163,164]. Therefore, we propose that this should be the primary metal 
ion-binding site in KGNK-6×His, as well.   
 
5.2.3. DNA cleavage experiments with the KGNK-6×His protein 
The cleavage of a randomly selected pUC-EGFP plasmid by the KGNK-6×His enzyme 
was monitored by agarose gel electrophoresis in the presence of various amounts of Zn2+ ions. 
A pUC-EGFP plasmid DNAs served as the template. The transitions between its supercoiled 
(sc), open circular (oc) and linear (lin) forms was followed by agarose gel electrophoresis. 
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Subsequent double strand cleavages fractionate the linear DNA into small fragments of various 
sizes resulting in a smear on the agarose gel.  
 
 
 
Figure 5.8. Top: Agarose gel electrophoresis images showing the cleavage of pUC-EGFP 
(74 M for nucleotide pairs) by 2.8 M KGNK-6×His protein containing increasing amounts 
of Zn2+ ions. Each column in one experiment represents the catalytic activity after 0, 15, 60, 
120 min, from left to right. Gene Ruler 1kb Plus DNA ladder was loaded as a reference, and 
the untreated pUC-EGFP plasmid for negative control. Bottom: Evaluation of the gel pictures 
by ImageJ program [165] for quantitation of the various forms of DNA after 120 min.  
 
The purified KGNK-6×His protein has a low nuclease activity. The band of the 
supercoiled form of the plasmid starts to decrease in intensity, while the band related to the 
linear form also appears within 2 hours of incubation (Figure 5.8). Since the active center of 
the purified protein contains Zn2+ ions, this low activity is attributed to the inhibitory effect of 
the affinity tag. By adding Zn2+ ions to the reaction mixture in increasing amounts we could 
observe a significant increase in the catalytic activity. The maximum of the DNA cleavage 
activity was achieved between ~ 1:3 and 1:5 protein-to-Zn2+ molar ratio. Under these 
conditions, the band of the supercoiled form completely disappears at 60 min; even the band 
related to the open circular form shows a decreased intensity and smearing of the band of the 
linear form occurs as a result of the fragmentation due to efficient catalytic process. After a 
further increase of the metal ion concentration, at 1:10 protein-to-Zn2+ molar ratio, the catalytic 
activity starts to decline again.  
These results are in agreement with the observation that the catalytic activity of the 
KGNK-6×His protein is decreased compared to the KGNK protein (see e.g. the results of the 
cloning experiments for comparison), due to the inhibition effect of the C-terminal tag. 
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However, the increase of the DNA cleavage ability of the enzyme upon increasing metal ion-
to-protein ratio suggests that the added metal ion can compete for the 6×His sequence, which 
originally may bind to the free site of the catalytic Zn2+ ion (Figure 5.9 a) accounting for the 
coordinative inhibition. Thus, by binding to the 6×His sequence, the added metal ion enhances 
the catalytic activity.  
By saturating the histidines outside the catalytic center with one or two Zn2+ ions, H545 
may also be metallated on further addition of metal ion, preventing the generation of the OH– 
nucleophile by the side-chain of this histidine residue. The higher is the metal ion excess the 
higher is the probability of this type of coordination. This would cause the decrease of the 
catalytic activity under such conditions. It can not be excluded that the second or third metal 
ion, which most probably binds to the hexahistidine sequence, may also coordinate to H545, 
but the extensive formation of such complex would result in inhibition of the enzyme instead 
of the activation as observed in the catalytic experiments.  
 
 
Figure 5.9. a, Coordination of histidine residues inside the KGNK-6×His to an increasing 
number of Zn2+ ions in parallel with the increase of the Zn2+ : protein molar ratio. The histidines, 
coordinating to Zn2+ ion inside the nuclease active center, are green. H545 is orange, while 
other histidines outside the native NColE7 sequence are marked red. b, Calculated species 
distribution diagram of the Zn2+ – KGNK-6×His (P) system based on the estimated apparent 
stability constants related to the various suggested metal ion binding sites (cP = 2.8 µM). 
 
We attempted to simulate these complex formation processes by estimating and refining 
the apparent stabilities of the ZnxP species to obtain the species distribution best describing the 
catalytic experiments. Up to four bound metal ions were included considering the number of 
a
b
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binding sites potentially offering stability, which is high enough to enable the complex 
formation in micromolar concentration range. The logK' values obtained in this way are ~9.0 
for ZnP; ~5.3 for ~Zn2P; ~4.9 for Zn3P and ~4.7 for Zn4P. The first value is in agreement with 
those published for the Zn2+ affinity towards the HNH active center [163,164]. The values for 
Zn2P and Zn3P are consistent with Zn
2+ coordination towards the oligohistidine peptides 
binding one or two metal ions [166-168]. The hypothetical distribution diagram (Figure 5.9 b) 
shows that the formation of Zn4P species becomes significant at >5 fold Zn
2+ excess. Since 
under such conditions the inhibition of the DNA hydrolysis can be observed in accordance with 
the literature data on NColE7 itself [169], we suppose that the coordination site in Zn4P is most 
probably the H545 residue. Taking this into account, the stability related to the binding of the 
fourth metal ion is fairly high. An explanation of this could be a stability enhancing effect of 
further amino acid side-chains available for metal ion binding together with H545. 
Multiple explanations can account for the observations so far: (i) The cooperative action 
of the N- and C-termini is required for NColE7 to hydrolyze DNA. This kind of intramolecular 
allosteric activation mechanism may be sterically hindered by the C-terminal protein tag. This 
phenomenon would allow the fine tuning of the enzyme by optimizing the length of the affinity 
tag. The tagged enzyme can also be activated by the tag removal from the protein via an 
optimally positioned hydrolytically sensitive amino acid sequence either by using a specific 
protease or by Ni(II)-induced cleavage. (ii) The metal ion containing active center at the C-
terminus of NColE7 is close enough to the hexahistidine sequence to allow the coordination of 
this motif to the free site of the catalytic Zn2+ ion. This event would also inhibit the nuclease 
action, as it prevents the metal ion coordination to the scissile phosphodiester group, which is 
an essential step of the DNA cleavage. In such a mechanism of inhibition the enzyme could be 
reactivated by the addition of metal ions, which can effectively compete with Zn(II) for the 
hexahistidine binding site, but do not replace Zn(II) in the active center. (iii) Furthermore, the 
hexahistidine tag may also form a ternary complex with Zn2+ ions including the H545 residue, 
which is responsible for the formation of the nucleophilic attacking hydroxide in the catalytic 
reaction. 
 
5.2.4. Mass spectrometric analysis of the metal ion binding properties of the KGNK-
6×His 
  ESI-MS experiments were carried out to verify the feasibility of the hypothesis 
described in Figure 5.9 a concerning the formation of mono and oligonuclear complexes of 
KGNK-6×His. The experiments were executed by gradually increasing the concentration of the 
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metal ion up to ~ 4 equivalents of Zn2+ relative to the protein. The results of the measurements 
are presented in Figure 5.10. As the ICP-MS measurements indicated, the purified KGNK-
6×His protein binds approximately one equivalent of Zn2+. The mass spectrum without adding 
additional metal ion (Figure 5.10 a), shows the presence of the ZnP monocomplex as the major 
species, while the Zn2P complex containing two metal ions also appears. 
 
 
Figure 5.10. Deconvoluted monoisotopic MH+ m/z spectra of the KGNK-6×His protein 
solution containing increasing amounts of Zn2+. (a) The protein solution with approximately 1 
equivalent of Zn2+. (b), (c) and (d) after the addition of further 0.5, 1.0 and 3.0 equivalents of 
Zn2+, respectively. Panel (e) shows the estimated relative abundance of the various metal 
complexes of the protein as a function of the added Zn2+ equivalents. Green colour refers to the 
ZnP (Zn2+ : protein = 1 : 1) monocomplex; Zn2P is marked with blue, Zn3P with red; while the 
orangish colours refer to the further Zn2+ adducts containing more metal ions (Zn4P-Zn6P). 
 
  The mass spectrometric experiments revealed that the KGNK-6×His protein is able to 
bind more metal ions. Up to 6 bound Zn2+ ions have been detected by ESI-MS. Based on these 
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measurements the relative amounts of the complexes containing various number of metal ions 
were estimated and plotted versus the added Zn2+ equivalents (Figure 5.10 e). For this, we 
identified the major peaks of the mass spectra in Figure 5.10 a-d and assigned them to the 
potential Zn2+–KGNK-6×His species, which could be present in the solution (from the 
monocomplex till the six Zn2+ containing adduct). The list of the peaks considered for the 
calculation of the relative abundance diagram is shown in Table 5.2.  
 
Table 5.2. List of the deconvoluted monoisotopic MH+ ions, which were used to obtain the 
estimated relative abundance diagram in Fig. 4e. (a) column refers to the purified protein 
solution containing approximately 1 equivalent of Zn2+ ions. Data in (b), (c) and (d) columns 
refer to protein solutions with additional 0.5, 1.0 and 3.0 equivalents of Zn2+ ions, respectively. 
The differences between the calculated and measured masses are due to the deconvolution 
process. In some cases Na⁺ and K⁺ adducts were observed, which were also taken into account 
during the calculations. 
 
          Species   MH
+
(mono) calc: MH+(mono) measured: 
    (a) (b) (c) (d) 
KGNK-6×His +Zn²⁺ -1H⁺   17832.08 17832.00 17832.02    
  -1H⁺ + K⁺ 17871.05 17870.95       
KGNK-6×His +2 Zn²⁺ -2H⁺   17895.00 17894.97 17895.00    
  -1H⁺   17896.01     17895.92 17895.96 
  -3H⁺ + Na⁺ 17916.99     17916.92  
KGNK-6×His +3 Zn²⁺ -2H⁺   17956.92 17956.94 17956.95    
  -4H⁺   17958.93     17958.87 17958.95 
  -3H⁺ + Na⁺ 17980.91     17980.85  
  -6H⁺ + K⁺ 17993.94   17993.87    
KGNK-6×His +4 Zn²⁺ -3H⁺   18021.85     18021.80  
  -4H⁺   18020.85       18020.91 
  -6H⁺   18018.83   18018.93    
  -5H⁺ + Na⁺ 18042.83     18042.78  
  -3H⁺ + K⁺ 18060.75     18060.82  
KGNK-6×His +5 Zn²⁺ -4H⁺   18084.78     18084.75  
  -5H⁺   18083.77   18083.91  18083.88 
KGNK-6×His +6 Zn²⁺ -8H⁺   18144.67   18144.93  18144.88 
 
  We summed up the intensities of the peaks belonging to the same species at each 
titration state and then plotted the percentage of these complexes in Figure 5.10 e. The maximal 
percentage of the Zn2P complex of KGNK-6×His, expected to be catalytically most active, is 
observed in the presence of ~1.0–2.0 equivalents of Zn2+. Compared to the catalytic activity of 
the KGNK-6×His as a function of the Zn2+ concentration, this would infer that the Zn3P species 
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could still be active, while the increasing metal ion concentration results in further coordinated 
Zn2+ ions and inhibition of the nuclease action. Although some of the detected complexes may 
not form in significant amounts in dilute aqueous solutions and under the conditions applied in 
the catalytic experiments, these results support the considerations made in Figure 5.9 and the 
clearer interpretation of the catalytic properties of the enzyme, too. 
 
5.2.5. Influence of the His tag on the structural integrity of KGNK-6×His  
Temperature dependent SRCD measurement series were carried out with the KGNK-
6×His protein in the presence and absence of metal ion with the aim to study the thermal 
stability of the enzyme. Earlier it was suggested that the removal of the metal ion decreases 
thermal stability of NColE7 [170]. The results shown in Figure 5.11 indicate that the changes 
in the structure of the KGNK-6×His enzyme do not occur in a single step.  
 
 
 
Figure 5.11. Temperature dependent SRCD spectra of the Zn2+-loaded (top) and apo (bottom) 
forms of the KGNK-6×His protein.  
 
The first conformational change occurred between 25–35 C and this was significantly 
affected by the removal of the metal ion from the enzyme. Then the main melting process 
occurred at around 49 C. This probably reflects the conformational change of the central 
helical regions of the protein, which is not significantly influenced by the metal ion. The curves 
63 
 
recorded in the presence of metal ion could be satisfactorily fitted with a single process with a 
melting point around 50 C.  
The melting process at low temperature is most probably related to the HNH motif, 
which might be slightly more flexible and thus, more sensitive to the increasing temperature in 
the absence of the metal ion. A plausible explanation may be that the C-terminal fusion tag 
destabilized the interaction between the two termini of NColE7, which is responsible for the 
stabilization of the structure of the preformed catalytic site [171]. This effect is, however, 
influenced by the metal ion, suggesting that the coordinated His tag has a negligible disturbing 
effect on the structure of the protein. This also supports the above observations, that the 
complex effect of the 6×His sequence involves steric hindrance, but it also inhibits the enzyme 
activity by binding to the metal ion in the catalytic center.  
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5.3 DNA targeting by artificial nucleases 
 One of the aims of my PhD study is to design an artificial nuclease that can efficiently 
target a selected (proto-)oncogenic DNA sequence in human genome. For the optimal artificial 
nuclease design, a suitable DNA target sequence has to be selected, which is essential for the 
protein expression from an oncogene in a cancerous disease. Targeting of the selected sequence 
is straightforward with the CRISPR/Cas9 artificial nuclease system, as its DNA recognition is 
defined by the oligonucleotide sequence of the guide RNA, that hybridizes to the target DNA 
sequence. In the experiments described in this chapter, I have studied the ability of the 
CRISPR/Cas9 system to target selected DNA sequences within the epidermal growth factor 
receptor (EGFR) oncogene in A549 human lung cancer cells. 
 
5.3.1. Construction and optimization of CRISPR/Cas9 system for targeting the epidermal 
growth factor receptor (EGFR, ErbB1) oncogene 
Inside the CRISPR/Cas9 complex, the gRNA must be properly formulated to target the 
correct region of genomic DNA. The gRNA binds to the corresponding DNA sequence 
allowing the Cas9 enzyme to cleave the genome close to the PAM site, as described in more 
detail in the literature review, section 2.3.3. The pX458 plasmid was chosen for our study 
because it has already been successfully applied earlier [59]. It provides ampicillin resistance 
as a selectable marker in E. coli and offers green fluorescent protein (GFP) expression for 
tracking in mammalian cells. A map of pX458 is shown in Appendix A.3. This plasmid allows 
for expression of Cas9 and for the transcription of the CRISPR single guide RNA (sgRNA) 
simultaneously. 
The sgRNA sequences hybridizing to the DNA target sequences within the epidermal 
growth factor receptor (EGFR) oncogene (Homo sapiens transcript variant 1, mRNA) in A549 
cancer cells were designed by Guide Design software (http://crispr.mit.edu/) as shown in Table 
5.3. These exons to be targeted were chosen due to their role in the EGFR oncogene function 
[172,173]. I also selected one targeted site on exon 17 based on the literature, since it 
demonstrated high genome editing efficiency to be used as a positive control [174]. The 
crispr.mit.edu database compares the possible target 20 base pair (bp) DNA sequences to the 
rest of the human genome to determine their frequency of appearance. The sequences are then 
given a score from 0-100%. The higher the score the less often the target is found elsewhere, 
meaning that using this sequence in the guide RNA would lead to very few off-target 
interactions. Sequences with a score over 85% were saved for use in the experiments. The 
sgRNA Exon 21* (score 67%) was chosen to verify the effect of the score parameter on the 
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CRISPR/Cas9 activity later. The position of the selected sequences in the gene of the EGFR is 
shown in Appendix A.4. 
The gRNAs include an additional G base at the 5’ termini of the selected sequences and 
the forward and reverse sequences have CACC and CAAA 5’ overhangs, respectively. The 
remaining 20 nucleotides hybridize with a 20 nt target sequence upstream of the PAM sequence 
in the oncogene. The forward and reverse gRNA sequences were annealed together as described 
in Appendix A.5. 
 
Table 5.3. List of the designed sequences of CRISPR single guide RNA for EGFR oncogene 
targeting. Exon 19M was selected from the literature [172], the target of this sgRNA is located 
adjacent to a PAM sequence only in mutant EGFR, but not in the normal gene. Thus, Cas9 
activity is only expected to occur at the mutant locus. 
 
Single guide 
RNA name 
Single guide RNA sequence and overhang Score percentage 
Exon 1-CGG 5’  5’-caccgCTGCGCTCTGCCCGGCGAGT-3’ 
3’- 3’-    cGACGCGAGACGGGCCGCTCAcaaa-5’ 
90% 
Exon 1-GGG 5’- 5’-caccgTGCGCTCTGCCCGGCGAGTC-3’ 
3   3’-    cACGCGAGACGGGCCGCTCAGcaaa-5’ 
90% 
Exon 17 5’-caccgAGATCCCGTCCATCGCCACT-3’ 
3’-    cTCTAGGGCAGGTAGCGGTGAcaaa-5’ 
89% 
Exon 19 5’- caccgTAAAATTCCCGTCGCTATCA-3’ 
3’-     cATTTTAAGGGCAGCGATAGTcaaa-5’ 
94% 
Exon 19M 5’-caccgATTAAGAGAAGCAACATCTC-3’ 
3’-    cTAATTCTCTTCGTTGTAGAGcaaa-5’ 
n.d. 
Exon 20 5’-caccgAGCCTACGTGATGGCCAGCG-3’ 
3’-    cTCGGATGCACTACCGGTCGCcaaa-5’ 
86% 
Exon 21* 5’-caccgCAAGATCACAGATTTTGGGC-3’ 
3’-    cGTTCTAGTGTCTAAAACCCGcaaa-5’ 
67% 
Exon 21** 5’-caccgATACTTGGAGGACCGTCGCT-3’ 
3’-    cTATGAACCTCCTGGCAGCGAcaaa-5’ 
97% 
 
 The pX458 plasmid was digested by BbsI restriction endonuclease as shown in Figure 
5.12.  
 
 
 
Figure 5.12. Schematic representation of cloning of the guide sequences into the cloning site 
of the pX458 plasmid.  
Ligation
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The BbsI recognition sequence is located within the cloning site for sgRNA scaffold, as 
it is shown in detail in the literature review (Section 2.3.3). The success of the pX458 digestion 
was checked by 0.7% agarose gel electrophoresis: a single band (linear form) appeared at the 
expected size of about 10 kbp (lane 3 in Figure 5.13). 
 
Figure 5.13. Agarose gel electrophoresis of digested pX458 plasmid. 
 
The hybridized gRNA oligonucleotides were ligated with the cleaved plasmid by T4 
ligase, then the resulted plasmids were applied to transform DH5α competent E. coli for 
multiplication purpose. The purified plasmids were sequenced by using pX-F primer (5’-
gagggcctatttcccatgattccttc-3’) to confirm the successful insertion.  
 
 
Figure 5.14. Selected electropherograms of the sequenced plasmids. Underlined regions 
illustrate the presence of CRISPR single guide RNA sequences successfully cloned into pX458. 
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Based on the results shown in Figure 5.14, the CRISPR/Cas9 constructs (pX458-E1-
CGG, pX458-E1-GGG and pX458-E17-GGG) have been successfully generated and 
sequenced within plasmids that contain the chimeric sgRNA, Cas9 gene, and GFP gene. 
 
5.3.2. Screening of CRISPR/Cas9 system on mammalian cell culture 
5.3.2.1.Transfection of the cancer cells 
A549 human lung cancer cells were selected for the transfection experiments because 
they overexpress EGFR. Targeting the EGFR oncogene should influence the amount of the 
expressed protein. The transfection efficiency, i.e. the percentage of cells that are transfected 
compared to the entire population, was checked by flow cytometry. In this experiment, the cells 
expressing the GFP are detected. According to the results, the transfection efficiency by pX458 
plasmid which contains the guide RNA reached up to 68% within few optimization steps 
(Figure 5.15). This is a reasonably high value to enable the CRISPR/Cas9 system to 
successfully perform its genome editing function  
 
 
Figure 5.15. Measurement of GFP expression by flow cytometry in A549 cells transfected by 
pX458 plasmid using Lipofectamine 3000 transfecting agent. a) transfection efficiency of the 
original pX458 and b) transfection efficiency with the pX458-E1-GGG after inserting the guide 
RNA. 
 
5.3.2.2. Genomic DNA extraction and sequencing 
The genomic DNA was extracted from the transfected cells, as well as from the control 
cells including the non-transfected cells after incubation for four and seven days. For this, we 
used DNeasy Blood and tissue kit (Qiagen). The direct sequencing of the targeted DNA 
segments to check the EGFR oncogene knockout efficiency of the applied CRISPR/Cas9 
systems was not successful, because this DNA preparation did not provide enough template. 
Therefore, the target sites were amplified in PCR using Dream Taq-DNA polymerase and 
specifically designed primer pairs for the different targeted sites (Appendix A.6). These primer 
pairs were complementary to the upstream and downstream sequences around the target 
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sequences. The PCR products were sequenced by Sanger sequencing to determine whether the 
targeted gene was edited. 
CodonCode Aligner software was applied for sequence data analysis [175], and the 
TIDE (Tracking of Indels by Decomposition) tool [176] was applied for the analysis of 
CRISPR/Cas9 activity. TIDE determines the spectrum and frequency of targeted mutations 
generated in a pool of cells by e.g. the CRISPR/Cas9 system. The analysis is based on the input 
of CRISPR single guide RNA sequence, control sample sequence and transfected sample 
sequence (using *.ab1 extension). The web tool reports the identity of the detected indels and 
their frequencies. 
 
 
Figure 5.16. a, CodonCode Aligner sequences of EGFR demonstrating CRISPR/Cas9 activity 
after seven days transfection. Top sequence represents control sequence without gene knockout. 
Highlighted region shows the region complementary to CRISPR single guide RNA. Bottom 
sequence shows a slight increase of the background noise, due to the low extent of the DNA 
modification. b, TIDE data demonstrate the CRISPR/Cas9 activity by showing level of 
decomposition and aberration in sequences. Dark green sample represents the control sequence 
showing no decomposition. Light green represents test sequence illustrating slight increase in 
decomposition c, TIDE data show the probability of insertions or deletions, which correlates to 
mutation efficiency observed to be 7.5%. 82.8% represents the wild type DNA without any 
mutation. 
total eff. = 7.5 %
a
b
c
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According to the sequencing results of the DNA from the control and the transfected 
samples, there is a tiny increase in the noise beyond the complementary region of single guide 
RNA due to the effect of mutations in this portion of the sequence. TIDE analysis detected 
differences between the control and CRISPR/Cas9-treated sequences. It revealed a mutation 
efficiency of 7.5% for sgRNA targeting exon 17 after seven days incubation period with the 
CRISPR/Cas9 as shown in Figure 5.16. This validates the specificity of the designed guides, 
however, the efficiency of this system is low and requires further optimization is required in 
the future. 
 
5.3.2.3. RNA extraction and qRT-PCR analysis 
Total RNA was extracted from the cells transfected with CRISPR/Cas9 plasmid 
targeting exons 1 and 17 of the EGFR gene and with the empty CRISPR/Cas9 plasmid (mock), 
as well as from the untransfected control cells (Appendix A.7). Quantitative real-time PCR 
(qRT-PCR) was applied to measure the amount of the transcribed RNA and thus, to detect the 
knockout level of the target gene in A549 cells. Various sets of designed primers were used for 
exons 1 and 17 in addition to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
encoding the positive control sequence as a reference gene (Table 5.4). The expression level of 
EGFR as the target gene was normalized to an average of GAPDH gene.  
 
Table 5.4. Details of the oligonucleotide sequences used for qPCR analysis. 
 
Gene  Forward and Reverse primers 
GAPDH  GTCTCCTCTGACTTCAACAGCG 
ACCACCCTGTTGCTGTAGCCAA 
EGFR-Exon 1  AGTCGGGCTCTGGAGGAAA 
AGCTCCTTCAGTCCGGTTTT 
EGFR-Exon 1*  AAGGATCCTGACTCCGTCCAGTAT 
TTGGATCCTGTAAATTTCTCATGGGC 
EGFR-Exon 17  TGCCATCCAAACTGCACC 
TGCGCTTCCGAACGATGT 
 
According to the results, the CRISPR/Cas9 system targeting EGFR exon 17 induced 
20% decrease in EGFR mRNA expression level after four days incubation period (Figure 
5.17). The level of EGFR gene expression was most probably decreased due to the small 
insertions or deletions (indels) as detected in DNA sequencing experiments (Figure 5.16). 
These mutations within the target sites may induce the shift of the reading frame and/or 
premature stop codons, leading to the expression of a truncated protein of target gene or 
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preventing gene expression [177]. Promising preliminary results have been obtained with 
other targets, as well, but these experiments need further optimization. 
 
 
 
Figure 5.17. EGFR knockout efficiency was determined by qRT-PCR in A549 cells transfected 
by CRISPR/Cas9 target the EGFR oncogene following the recommended transfection protocol. 
EGFR mRNA expression levels were measured four days post-transfection. Values are 
normalized to untreated sample. Data are presented as means ± SD. 
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5.4. Delivery of the artificial nucleases into the mammalian cells 
The success of the selected genome editing technique is influenced by the effectivity of 
the delivery system used to carry the nuclease to the specific target cells. By improvement of 
the delivery and specificity of the ZFNs and CRISPR-Cas9 system, the current challenges could 
be overcomed, promoting this technology to be used therapeutically. Chemical delivery 
methods are being considered to be the most promising. For this reason, a novel cationic water-
soluble lipopolymer (WSLP) was applied to encapsulate the pDNA for transfection in this work. 
The water-soluble cationic lipopolymer (WSLP) was obtained by the modification of high 
molecular weight (HMW) branched poly(ethylenimine) (PEI) with cholesteryl chloroformate. 
It was characterized and assessed for better cellular membrane permeability. This part of the 
work was conducted in strong collaboration with two research groups. Researchers Dr. Edit 
Csapó and Dr. Anita Ditta Ungor provided facilities and helped with the measurements on the 
nanoparticle characterization, while Dr. Monika Kiricsi, Nóra Igaz and Mohana Krishna 
Gopisetty helped with the experiments using cancer cell lines. 
 
5.4.1. Synthesis and characterization of water-soluble lipopolymer 
WSLP was prepared from PEI and cholesteryl chloroformate as described in the 
experimental section. The reaction is schematically depicted in Figure 5.18. Due to the 
balanced ratio between the hydrophilic PEI and lipophilic cholesterol, the prepared WSLP is 
well soluble in water. The critical micelle concentration (CMC) of the WSLP was determined 
to be 0.35 ± 0.03 mg/mL by using dye solubilization method as it is described in more detail in 
the Appendix A.9. 
  
Figure 5.18. Schematic representation of the WSLP synthesis and the complex formation 
with the pDNA. 
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5.4.1.1. Particle charge detection 
The average molecular weight of PEI was not provided and therefore, we had to 
determine it. For the average molecular mass of PEI Mw ~ 139±1 kDa was obtained from DLS 
measurements (it can be found in the Appendix A.8), however, the same method was not 
suitable for the determination of the molecular mass of WSLP, because of the artefacts arising 
from the light scattering of some aggregates. The WSLPs obtained by cholesterylation of low 
molecular weight PEI are usually characterized by NMR and MALDI TOF MS in terms of the 
molecular weight and cholesterylation extent [104,133,178-184]. These methods perform well 
with small and medium size molecules, but become of limited use for compounds with the 
molecular weight with several hundreds of kDa. The broadening effect of the NMR bands due 
to the slow molecular tumbling can already be experienced with the WSLP having Mw > 10 
kDa [105,185-186] while according to our knowledge no MS data are published for high 
molecular weight PEI or WSLP. Therefore, we were looking for a readily available simple 
method for checking the cholesterylation extent. Since cholesterylation or the modification in 
general, may affect the specific charge of the polymer both through the reaction with the amine 
groups and through increasing the molecular weight, such measurements could provide useful 
information, independently of the size of the polymer. The specific charge of the polymers was 
determined by the titration of sodium dodecyl sulfate (SDS) by PEI and WSLP, and checking 
the charge neutralization points. As it can be seen in Figure 5.19, the negative streaming 
potential continuously increased by the increase of the amount of the polymers. Based on the 
measured data, the charge compensation occurred upon adding of 6.5 mg PEI or 14.8 mg WSLP 
into the particle charge detector (PCD) cell. Knowing the applied amount of SDS, the specific 
charges of PEI and WSLP were calculated, to be q(PEI) = 15.38 mmol g–1 and q(WSLP) = 6.76 
mmol g–1, respectively. Using these data and the molecular weight of the initial PEI, the 
protonated fraction of PEI can be estimated. The theoretically maximal specific charge of the 
applied PEI polymer is 23.22 mmol g–1, suggesting that ~ 66% of the nitrogens are protonated 
in PEI under the measurement conditions. This is in very good agreement with the suggested 
values published in the literature for branched PEI molecules determined from acid-base 
titrations [187].  
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Figure 5.19. Titration of SDS with PEI or WSLP solutions for the detection of the charge 
neutralization point in a charge particle detection experiment, as described in the experimental 
section.  
 
It can also be concluded that the specific charge has decreased in the cholesterylation 
step. The ratio of q(WSLP)/q(PEI) is ~ 0.44, meaning that the WSLP has 56% less specific 
charge than PEI. Since the specific charge (q) depends on the molecular weight  and the number 
of charges in a single molecule (n+)the decrease of the specific charge may occur both by the 
increase of Mw and decrease of the number of the protonated nitrogens according to Equation 
5.1.  
 
q [
𝑚𝑚𝑜𝑙
𝑔
] =  
1
Mw
𝑛+1000          (5.1) 
 
The cholesterylation occurs at more reactive primary amine groups which have to be 
deprotonated under the reaction conditions, but they might be protonated in a buffer solution at 
pH ~ 7. An initial PEI molecule with Mw of 139 kDa contains 3227 nitrogens, out of which 
~ 2138 are protonated based on the measured specific charge. The increase of the Mw may play 
major role in the decrease of the specific charge of WSLP compared to PEI, if the number of 
protons at the nitrogens does not change as the consequence of the modification. In this case 
the increased Mw can be calculated from Equation 1, based on the specific charge value of the 
WSLP. This calculation yields ~ 316.5 kDa as the new Mw. This molecular weight is the sum 
of the original 139 kDa of the PEI and the mass increase due to the cholesterylation, i.e: 
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316492 = 139000 + x(449.11 – 35.45). Here x is the number of the conjugated cholesteryl 
groups per a PEI polymer, which can be easily calculated to be x ~ 429. This reveals that 
approximately 13% of the nitrogens have been cholesterylated. On the other hand, we also may 
carry out the calculation assuming that the charge on the new WSLP molecule is decreased by 
the number of the cholesteryl groups attached to the nitrogens of PEI. In this case Equation 5.2 
will be used for the calculation of x in its following form:  
 
6.76 =  
1
139000+𝑥(449.11 – 35.45)
(2138 − 𝑥)1000       (5.2) 
 
From this, x ~ 316 is obtained. Thus, ~ 10% is suggested for the possible fraction of the 
cholesterylated nitrogens. The molecular weight of the synthesized copolymer is ~ 269.7 kDa 
by this assumption. The real number of the attached cholesteryl groups might be between the 
above two values assuming that no further deprotonation of the WSLP is caused by the 
modification. This calculation provides closer estimates for the possible domains of important 
parameters such as the molecular weight and the charge content of the newly prepared polymer.  
 
5.4.2. pDNA condensation efficiency of the water-soluble lipopolymer 
WSLP/pDNA complexes are usually prepared by adjusting the mass or N/P ratios. It 
has to be mentioned that the two types of preparation can not be directly compared with each 
other. The N/P ratio is the ratio of the number of nitrogen atoms of WSLP and the number of 
the phosphorous atoms of plasmid DNA. The number of nitrogen atoms is obtained by dividing 
the molecular weight of the polymer with the molecular weight of the monomer (there is one N 
atom in a monomer) and P atoms are calculated as 2000×kb of the plasmid DNA. For this, the 
knowledge of the molecular weight, i.e. the extent of the modification of PEI, as well as the 
protonation state of the polymer is essential. These parameters are usually very difficult to 
determine precisely.   
We optimized the loading efficiency of WSLP using pEGFP-N3 and pX458 plasmids 
within both the mass and the N/P ratios ranging from 1.25 to 20.0 as it is described in more 
detail in the Appendix A.10. DNA encapsulating ability of WSLP was monitored by agarose 
gel electrophoresis. The results on N/P ratio series are shown in Figure 5.20.  
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Figure 5.20. Agarose gel electrophoresis picture of naked pEGFP-N3 plasmid and WSLP/ 
pEGFP-N3 complexes formed at N/P ratios 1.25, 2.5, 5, 10 and 20 in lanes 3–7, respectively.  
 
On an increase of the N/P ratio, free DNA could not be detected on agarose gel when 
the value of N/P ratio reached 5/1, confirming the effectiveness of condensation by the polymer. 
This is due to the fact that positively charged head groups of WSLP interact strongly with the 
negatively charged phosphate ions in the backbone of plasmid DNA independently of its 
nucleotide sequence. Nevertheless, the specific charges (ratio of the charge of anion or particle 
for its mass) put the case more clearly, since the specific charge of the DNA which should be 
3.24 mmol g–1, can directly be compared with that of the polymer. At 5/1 N/P ratio the reaction 
mixture was constructed by mixing 1.00 μg of pDNA with 0.76 μg of WSLP. Based on the 
specific charges this corresponds to a positive/negative charge ratio of 5.14/3.24, i.e. the total 
charge of the WSLP/pDNA system is positive, while at N/P = 2.5/1 is still negative. This is in 
good agreement with the fact that the band of the DNA can be detected at N/P = 2.5/1 ratio on 
the agarose gel, although its mobility is less than that of the free DNA. At the same time the 
DNA band at N/P = 5/1 ratio does not appear on the gel. At the same time, the mass ratio of 5/1 
would correspond to a positive/negative charge ratio of 33.8/3.24, which means that this particle 
is already highly positively charged. Thus, by measuring the specific charge of the polymers 
the preparations using various types of ratios become comparable with each other.  
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5.4.3. Characterization of WSLP/DNA complexes 
Preparations of WSLP/pEGFP-N3 and WSLP/pX458 complexes with various 
composition ratios were also investigated by DLS to determine the particle size and ζ-potential. 
The loading of plasmids into the polymer with defined colloidal and surface properties plays a 
major role in controlling stability, biodistribution, and intracellular fate of formulated plasmids. 
In contrast to the large size of naked DNA [185] complex formation between WSLP and 
plasmid DNA resulted is small size particles. For WSLP/pEGFP-N3 complexes, the mean 
particle size was in the range of 53.1 to 268.6 nm depending on the N/P ratio. ζ-potential of 
WSLP/DNA complexes increased with the increase of the charge ratio. At the N/P ratio of 
2.5/1, it was –22.4 mV, but increased to +15.3 mV when formulated at N/P ratio of 20/1 as 
shown in Table 5.5. The size and ζ potential values for WSLP/pX458 complexes differ from 
the WSLP/pEGFP-N3 complexes as shown in Table 5.6.  
 
Table 5.5. The average size and ζ -potential values of WSLP/pEGFP-N3 plasmid complexes at 
different N/P ratios.  
 
N/P ratio d (nm) ζ-potential (mV) 
1.25/1 53.1 ± 9.5 -22.4 ± 0.4 
2.5/1 93.2 ± 9.2 -25.3 ± 0.2 
5/1 138.8 ± 24.6 -20.3 ± 1.1 
10/1 142.5 ± 14.8 +1.9 ± 0.2 
15/1 163.8 ± 39.2 +12.3 ± 0.5 
20/1 268.6 ± 19.2 +15.3 ± 1.3 
WSLP 36.7 ± 3.5 +61.6 ± 0.4 
 
Table 5.6. The average size and ζ -potential values of WSLP/pX458 plasmid complexes at 
different N/P ratios.  
 
N/P ratio d (nm) ζ-potential (mV) 
2.5/1 61.0 ± 4.7 -19.7 ± 4.9 
5/1 63.1 ± 7.6 -3.2 ± 3.3 
10/1 133.2 ± 5.2 +23.1 ± 4.5 
20/1 131.9 ± 3.5 +28.9 ± 1.7 
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The WSLP/pEGFP-N3 complexes were characterized by SEM and TEM. The recorded 
images are shown in Figure 5.21. Both SEM and TEM detected the particle sizes being in good 
agreement with the values determined by DLS. The morphology of the WSLP/pEGFP-N3 
complex (5/1 mass ratio preparations) is shown in Figure 5.21A, B. The significant increase in 
size of the pDNA/WSLP nanoparticles (> 100 nm; Figure 5.21D) in comparison with the 
WSLP itself (< 50 nm; Figure 5.21C) is clearly demonstrated by TEM, supporting the 
successful condensation of the negatively charged pDNA by the cationic lipopolymer. Also, 
the pure WSLP in most cases showed fibrous structure on solid surfaces (e.g. copper grid) as 
can be also seen on the Figure 5.21C, while the morphology became nearly spherical-like upon 
complexation with DNA. The image shown in Figure 5.21D suggests a core-shell-like 
architecture of the pDNA/WSLP complex, which is assumed based on the different electron 
diffractions of the two components, due to their significantly distinct molecular weight. 
However, we could not unequivocally confirm such structure upon analyzing more particles 
(Figure 5.21E and 5.21F). 
 
 
 
Figure 5.21. A and B: SEM images of the WSLP/pEGFP-N3 complex using 5/1 mass ratio 
preparations under different magnifications. C: TEM image of the WSLP itself. D, E and F: 
TEM images of selected WSLP/pEGFP-N3 nanoparticles from the 10/1 NP ratio preparation. 
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5.4.4. Cytotoxicity assay 
The cytotoxicity of WSLP and WSLP/pEGFP-N3 complexes was determined on A549 
and HeLa cell lines after 24 h and 48 h incubation at 37 °C by MTT assay as shown in Figure 
5.22.  
  
 
Figure 5.22. In vitro cytotoxicity analysis of naked DNA, WSLP and WSLP/pEGFP-N3 at 
various N/P ratios on (A) A549 and (B) HeLa cells using MTT assay. Viability of the naked 
DNA, WSLP and WSLP/pEGFP-N3 treated cells was normalized to the untreated controls. 
 
According to the results the polymer is slightly toxic to the cells at 304 ng/well WSLP 
concentration. However, cell viability decreased significantly upon increase of the WSLP 
concentration, which indicates a remarkable dose-dependence of cytotoxicity. We have also 
checked the cytotoxicity of the WSLP/pEGFP-N3 preparations as a function of the ratio of the 
two components.  
The average cell viabilities upon treatment with WSLP/pEGFP-N3 of increasing N/P 
ratios from 5 to 20, decreased from ~84% to ~36% for A549 cells, and from ~80% to ~8%, for 
HeLa cells after 24 h. It is important to note that upon association of the WSLP with the pDNA, 
the toxic effect did not increase compared to the WSLP itself. Cytotoxicity was reasonably low 
even at 10/1 N/P ratio for A549 cells, nevertheless it depended remarkably on the type of the 
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applied cell. The microscopic images of the cells treated with WSLP/pEGFP-N3 complexes 
show that the majority of the cells are destroyed by the excess of the WSLP (Appendix A.11). 
We have also compared the toxic effect of the WSLP preparations with the starting 
HMW PEI, as well as with the commercial standard transfection reagent Lipofectamine 3000. 
The results are included in Figure 5.23, showing that PEI is extremely toxic to the cells, while 
upon cholesterylation, the resulted WSLP performs similarly to Lipofectamine.  
 
 
Figure 5.23. Comparison of the cytotoxic effect of WSLP with the high molecular weight PEI 
starting material and the standard commercial transfection agent LipofectamineTM 3000 in in 
vitro cytotoxicity analysis of naked on A549 cells at various amounts of the reagents using 
MTT assay. Viability of the treated cells was normalized to the untreated control. While the 
numbers shown for PEI and WSLP relate to the mass in ng of the substances per well, for 
Lipofectamine the 0.3 L is the amount providing the optimal concentration as suggested by 
the supplier.  
 
5.4.5. In vitro transfection 
The transfection efficiency of WSLP/pEGFP-N3 complexes at various N/P ratios was 
determined in A549 and HeLa cells as shown in Figure 5.24. According to the results of flow 
cytometry, the most efficient transfection was achieved at 20/1 N/P ratio in both cell lines. This 
can be surprising, since the 20/1 N/P ratio preparation caused increased cytotoxicity in the MTT 
assays compared to the preparations with lower N/P ratios. This effect is often reported in the 
literature [133]. It may be explained by the fact that the stably transfected cells may efficiently 
proliferate during the incubation after the transfection procedure. Indeed, the transfection 
efficiency reached 36.5% in the case of A549 cells and 64.3% in the case of HeLa cells. These 
values render this type of WSLP promising for its applicability in in vivo transfection 
experiments after the optimization of the cytotoxic side-effect.  
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Figure 5.24. Flow cytometric analysis of in vitro transfection efficiency. A) A549 and B) HeLa 
cells were transfected with WSLP/pEGFP-N3 complexes of various N/P ratios.  
 
As another proof of the successful gene delivery using WSLP/DNA complexes is the 
direct visualization of the expressed enhanced green fluorescent protein (EGFP) in A549 cells 
was confirmed using an inverted fluorescent microscope.  
 
 
Figure 5.25. Fluorescence microscopic images of A549 cells transfected by WSLP/pEGFP-N3 
complexes at 10/1 N/P ratio after 48 h incubation time. PEI was used for comparison. The scale 
bar represents 500 μm and it is same for all images in this figure. 
A549
A B
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Figure 5.25 clearly indicates that GFP expression is more intense in cells transfected 
with the WSLP/pDNA than with PEI/pDNA complexes at 10/1 N/P ratio. The fluorescence is 
more diffuse when PEI was applied instead of WSLP, which can be easily explained by the 
phase contrast images, showing that PEI is much more toxic than WSLP. 
GFP expression was also observed using confocal microscopy   after transfected A549 
cellular nuclei were stained with Hoechst fluorescent dye. The results revealed that more GFP 
is expressed using WSLP as transfection agent than with PEI (Appendix A.13).  In other words, 
the WSLP/DNA complexes showed higher intracellular distribution than PEI/DNA. 
 
5.4.6. Assessment of WSLP/pX458 complexes activity by in vitro gene knockout assay 
After the high transfection efficiency was achieved by using the WSLP carrier, the 
genome editing ability of the designed CRISPR/Cas9 system was monitored, demonstrating the 
biological activity of WSLP/pX458 complexes at 10/1 and 20/1 N/P ratios. The genomic DNA 
was extracted from the transfected A549 cells, sequenced and analysed as described previously 
in 5.3.2.2 section. A mutation efficiency of 8% and 6% for sgRNA targeting Exon 17 was 
obtained after seven days incubation period with WSLP/pX458 10/1 and 20/1 respectively as 
shown in Appendix A.14. These results are comparable to the mutation efficiency obtained 
using the commercial Lipofectamine as transfecting agent. This demonstrates the feasibility of 
applying the cationic WSLP in combination with genome editing materials, which could 
broaden the application of nanomaterials in gene therapy. These experiments still need 
optimization for more effective cancer gene therapy. 
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5.5. Development of specific and regulated NColE7-based zinc finger artificial 
nuclease 
To decrease the probability of the off-target activity of the artificial nucleases, novel 
zinc finger ANs were designed in our laboratory, based on the NColE7 nuclease domain instead 
of the NFokI nuclease domain. NColE7 was selected as the nuclease domain in the new ANs 
because of the knowledge available in the literature and from previous experiments in our 
laboratory, as discussed in the literature review 2.3.4. During the AN design, the nuclease 
domain NColE7 was divided into two parts and then joined by a zinc finger protein, which 
recognizes a selected specific DNA sequence [79]. In the prototype ANs, the ZF is zinc finger 
protein containing three finger units, identical to that in the crystal structure with the PDB Id: 
1MEY. The two segments of NColE7 are expected to fit together into a functional unit upon 
DNA binding. The regulatory N-terminal segment then activates the catalytic C-termial 
sequence. This is a positive intramolecular allosteric activation process. As mentioned earlier, 
the NX-ZF-CY (where NX is the N-terminal segment and CY is the C-terminal segment of 
NColE7 with X and Y referring to the number of residues involved, respectively) type ANs 
could achieve specificity and moderate activity, but the regulation was only slightly functional 
[77]. Therefore, our goal was to develop a regulated zinc finger nuclease in which the nuclease 
domain itself is inactivated in the absence of a specific DNA target sequence. 
We chose the CY–ZF–NX model for further optimization, in which the N-terminus of 
the ZF is close to the C-terminus of NColE7, while the C-terminus of the ZF is close to the N-
terminus of NColE7. Thus short linkers can be designed to directly bind the termini of the 
proteins to form a continuous circular sequence in the model. By deleting a selected amino acid 
from the NColE7 sequence the circular AN can be linearized. In the resulting CY–ZF–NX 
proteins X + Y is always 130, one amino acid less than the total number of amino acids in 
NColE7. C123–ZF–N7 was computationally analysed by molecular dynamics (MD) 
simulations and found to be promising in terms of catalytic activity, and the structural 
robustness [79]. 
 
5.5.1. Design of new zinc finger nuclease variants 
The amino acid to be deleted from the NColE7 part can in fact be selected arbitrarily. 
Along this path genes of several new ZFN variants were established by Dr. Eszter Németh as 
CY-ZF-NX, together with their CY-ZF pairs in which the N-terminal activator domains have 
been deleted (Figure 5.26).  
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Figure 5.26. Schematic representation of the CY-ZF-NX ANs and their truncated pairs. The C- 
and N-terminal residues of NColE7 are shown in green and red, respectively; the ZF array is in 
blue, and the short linker sequences joining these units are in black. 
 
Protein expression experiments were performed in BL21 cells for comparison of the 
selected CY–ZF–NX and CY–ZF protein pairs to detect their different levels of the toxicity. 
OD600 of the bacterial cultures containing transformed BL21 cells was registered after the 
protein expression was induced by IPTG at different incubation times (Figure 5.27).  
 
 
Figure 5.27. In vitro catalytic experiment of NX–ZF–CY, CY-ZF-NX and CY-ZF ANs inside 
BL21 (DE3) E. coli cells. The blue box refers to the most promising AN pair. 
 
Catalytic domain (inactive) Specific DNA binding domain ActivatorL L
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The bacterial growth was not significantly influenced by most of the proteins expressed, 
including control experiments, as well, while it was found that both the C123-ZF-N7 and C123-
ZF proteins were toxic indicating that the allosteric control is not functional in these ANs. 
However, C45-ZF-N85 was only active in the presence of N85 activator domain suggesting 
that this variant is under allosteric regulation.  
 
5.5.2. Proteins used in this work 
The cytotoxicity of NColE7 is based on its non-specific DNA cleavage, i.e. its nuclease 
activity. However, we expected that the new ANs will cleave the DNA in a specific way. 
Therefore, we have first isolated the DNA from the BL21(DE3) cells treated by the various 
CY–ZF–NX variants. The results are shown in Figure 5.28. 
 
 
 
Figure 5.28. Agarose gel electrophoresis picture of the DNA preparations from BL21 (DE3) 
E. coli cells transformed by plasmids encoding for various CY–ZF–NX ANs.  
 
The gel electrophoresis picture clearly shows the difference between the nuclease 
behavior of the C45–ZF–N85 and its C45–ZF truncated pair. The bands of the superhelical (sh) 
and open circular (oc) plasmid DNA are clearly visible in the presence of the truncated protein, 
but disappeared due to their digestion by C45–ZF–N85. This suggests non-specific DNA 
cleavage by the designed AN. However, the large size DNA, which might be the genomic DNA 
extracted from the bacteria, was not fragmented is the same way. This might be explained by 
the competitive effect of the E.coli DNA binding proteins preventing non-specific cleavages. 
Surprisingly, similar effect was observed with the C85–ZF–N45 and C85–ZF AN pairs, which 
was not observed in the cytotoxicity experiment. The C123–ZF–N7 and its C123–ZF pair did 
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not show significant DNA cleavage, although both of these ANs were cytotoxic. Thus, the 
cytotoxicity seems to be influenced by multiple factors.  
Since the C45–ZF–N85 vs. C45–ZF AN pair appeared to be different both in the 
cytotoxicity and in the DNA cleavage experiments, my following experiments focused on a 
detailed investigation of the C45–ZF–N85 protein.  
 
 
Figure 5.29. Amino acid sequences and computer models showing of the DNA binding of C45-
ZF-N85 protein and its mutants. 
 
To understand more about the function of N85 part in the allosteric activation of the 
new AN variants, two further mutations were performed within this region. (i) In C45-ZF-N85 
W160A mutant (abbreviated by W/A) a tryptophan was mutated to alanine. It has previously 
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been demonstrated that the corresponding W464A mutation leads to collapse of the secondary 
structure of NColE7 because this amino acid contributes to the proper folding and stabilizes the 
structure of the metal-binding HNH motif due to its extensive hydrophobic interactions [171]. 
However, the functional fold of the W464A NColE7 mutant is induced by binding of the DNA 
substrate. This phenomenon can be explored in the C45-ZF-N85 W160A mutant AN, as well. 
(ii) In C45-ZF-N85 R143G variant (abbreviated by R/G) an arginine was changed to glycine, 
influencing the catalytic activity of the enzyme [186]. The R447G mutation in NColE7 affects 
the number of the positively charged residues in the regulatory region and thereby also the 
interaction with DNA. Therefore, this mutation in C45-ZF-N85 is expected to decrease its non-
specific cleavage. Amino acid sequences and computer models of C45-ZF-N85 and its mutants, 
including also the truncated C45-ZF protein are shown in Figure 5.29. The results of the 
experiments concerning the solution structure and the nuclease activity of these proteins, where 
these investigations were possible, are presented in the following. 
In order to study the allosteric regulation of the C45-ZF-N85 NColE7-based artificial 
nuclease and to decrease the nonspecific DNA cleavage, the catalytic experiment was 
performed in transformed BL21 cells, similarly as described above. The DNA was purified 
from these bacterial cells and analysed by agarose gel electrophoresis (Figure 5.30). The results 
showed the nonspecific cleavage properties of C45-ZF-N85 in which the plasmid DNA is 
fragmented, while in the case of its mutants, the plasmid bands remained visible suggesting the 
decrease of the non-specific cleavage ability.  
 
Figure 5.30. Purified plasmids containing genes of C45-ZF-N85 and its mutants, run on 1 % 
(m/V) agarose gel. Gene Ruler 1kb Plus DNA Ladder served as the reference. 
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5.5.3. Expression and purification of the designed proteins 
The new AN proteins were expressed and purified to study their solution structure, 
interaction with DNA and Zn2+ ions, and their catalytic activity in vitro. The new pET-21a*-
SRHS plasmid (introduced in chapter 5.1) seemed to be useful for the purification of the 
artificial nuclease as a 6×His tagged protein by nickel-affinity chromatography, without any 
remaining amino acids after the Ni(II)-induced cleavage of the affinity tag. However, 
previously it has been shown that the 1MEY ZF protein used in the prototype ANs can itself be 
cleaved by Ni(II) ions, since it contains two SXH sequence motifs. Therefore, a mutation of the 
ZF motif according to the suggested protocol [160] was performed without changing its DNA 
binding specificity, prior to the further experiments. The modified ZF is denoted as ZF# in the 
following. The genes of C45-ZF#-N85 and C45-ZF# were then cloned into the pET-21a*-
SRHS plasmid using the BsmBI restriction enzyme. Based on the sequenced plasmids, the 
6×His-tagged proteins were overexpressed in BL21 (DE3) cells and purified on Ni(II)-NTA 
column. After this step, the protein samples were checked by SDS PAGE, showing the success 
of the affinity chromatography (Figure 5.31).  
 
 
Figure 5.31. The 12.5% SDS PAGE analysis of the purified C45-ZF#-N85-6×His and  C45-
ZF# -6×His proteins (collected fractions from nickel affinity chromatography). 
 
Due to the strong aggregation tendency of the ANs most of the protein precipitated and 
aggregated during the Ni(II)-induced cleavage of the 6×His tag. For this reason, this purification 
strategy was not successful in the case of these proteins. The process needs further optimization 
e.g. a reducing agent containing buffer. In parallel we have also carried out the expression and 
purification of the ANs in their designed forms.  
C45-ZF-N85, C45-ZF, the W/A the R/G mutant proteins were expressed in BL21 (DE3) 
cells and purified by a multistep cation exchange chromatography by Eniko Hermann and 
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myself [188]. The success of the expression and purification of the proteins was verified by 
SDS PAGE as shown in Figure 5.32.  
 
 
Figure 5.32. The 12.5% SDS PAGE analysis of the purified C45-ZF-N85 protein and its 
mutants. 
 
To characterize the purified proteins their solution structure was investigated by CD 
spectroscopy and their secondary structures were calculated from CD data using BeStSel 
program [162]. The results of the calculations obtained from the spectral region between 190 
and 250 nm are shown in Table 5.7. 
 
Table 5.7. The percentage of each secondary structural element in the tested proteins, calculated 
using the BeStSel program from their CD spectra.  
 
Protein Name α-Helix β-sheet Turn Others 
C45-ZF-N85 17.5% 26.9% 14.1% 41.5% 
C45-ZF 17.3% 25.7% 15.3% 41.6% 
C45-ZF-N85 W160A 13.1% 31.3% 15.7% 39.9% 
C45-ZF-N85 R143G 18.5% 21.1% 14.1% 46.3% 
 
The data obtained for the C45-ZF-N85 and the R/G mutant proteins show that this fold 
is similar  to that expected from the data of the independent ZF and NColE7 proteins. This may 
be surprising, since the functional structure is expected to be stabilized only in the presence of 
the DNA substrate. However, the CD data analysis does not reflect the tertiary structure. On 
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the other hand, the W/A mutant displays smaller fraction of the helical parts in agreement with 
the effect of this mutation in NColE7. The concentration of the C45-ZF protein and thus, the 
intensity of the CD spectrum was very low (~ 2 M) and therefore, the calculated values are 
considered to be ambiguous.  
We have also applied ESI-MS to determine the molecular weight of the purified 
proteins. The measurements with C45-ZF-N85 under acidic conditions revealed a Mw value, 
which is in good agreement with the expected one: 26057.0 Da (monoisotopic mass). It has to 
be mentioned that on the addition of ~ 5 equivalents of Zn2+ ions the protein could bind three 
equivalents of metal ion, and the catalytic center could only be saturated by the metal ion upon 
adding high excess of the Zn2+ ions.  
 
5.5.4. Plasmid cleavage activity of the C45-ZF-N85 artificial nuclease 
The catalytic activity of the purified C45-ZF-N85 and C45-ZF proteins was studied by 
using a nonspecific plasmid (pGEX-6P-1), which does not contain the zinc finger recognition 
site and a specific plasmid (pGEX-6P-1-Z0, abbreviated by Z0 in the following) that contains 
two recognition sites of the artificial nuclease opposite to each other (Figure 5.33).  
 
 
 
Figure 5.33. Scheme of pGEX-6P-1-Z0 plasmid in which two 1MEY recognition sites (shown 
in blue and red) are inserted into the SmaI restriction site of the original pGEX-6P-1 plasmid. 
The two green lines represent the expected double strand cleavage resulting in a linear plasmid 
with sticky ends.  
 
The Z0 plasmid was cleaved into open circular form by C45-ZF-N85 after 24 h but C45-
ZF did not cleave the DNA. This shows that the C45 catalytic motif can only function in the 
presence of an activator sequence, i.e. N85 is essential for the catalytic activity, indeed. On the 
other hand, the non-specific pGEX-6P-1 plasmid was not cleaved by either C45-ZF-N85 or 
C45-ZF. This proves the specificity of the artificial nuclease (Figure 5.34).  
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Figure 5.34. Cleavage of the pGEX-6P-1 and pGEX-6P-1-Z0 plasmids (12 nM) by 200nM 
protein. 200 nM ZnSO4 and 150 mM NaCl was adjusted in 20 mM Tris pH 7.9. The reaction 
mixtures were incubated up to 24 hours at 37 °C. The reactions were stopped by 1% (m/V) SDS 
and freezing, and subsequently run on 1 % (m/V) agarose gel. The untreated plasmids served 
as negative controls. Gene Ruler 1kb Plus DNA ladder served as the reference. 
 
The results shown in Figure 5.34 are the outcome of optimization experiments to adjust 
the ionic strength, Zn(II) and protein concentration, required for the specific and regulated 
nuclease activity. Finally, the concentrations of NaCl and Zn2+ ions concentrations were fixed 
at 150 mM and 200 nM, respectively. Double stand cleavage was expected, in which the 
superhelical form of the plasmid is converted to linear form but only single strand cleavage 
happened. This may be explained by the strong specific DNA binding of the AN protein 
sterically inhibiting the binding of a second protein molecule and the occurrence of cleavage 
on the opposite strand of DNA, under the measurement conditions. The above experiments 
demonstrated that it was possible to establish the reaction conditions under which the specificity 
and regulation of C45-ZF-N85 could be proved.  
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 The cleavage of pGEX-6P-1-Z0 plasmid by the C45-ZF-N85 was monitored by agarose 
gel electrophoresis in the presence of various amounts of Zn2+ ions (Figure 5.35). The protein 
is completely inactive in the absence of added Zn2+ ions. This suggests that the C45-ZF-N85 
was purified without, or with a minimal amount of zinc(II), bound in the catalytic center. The 
maximum of the DNA cleavage activity was achieved at 1:1 protein-to-Zn2+ molar ratio. Under 
these conditions, the supercoiled DNA changed to open circular form at 24 h. After a further 
increase of the metal ion concentration, at 1:2 protein-to-Zn2+ molar ratio, the catalytic activity 
is completely inhibited. 
 
 
Figure 5.35. Agarose gel electrophoresis images showing the cleavage of pGEX-6P-1-Z0 (12 
nM) by 200 nM C45-ZF-N85 protein containing increasing amounts of Zn2+ ions. Each column 
in one experiment represents the catalytic activity after 1, 3, 24 h, from left to right. Gene Ruler 
1kb Plus DNA Ladder was loaded as a reference, and the untreated pGEX-6P-1-Z0 plasmid as 
the negative control.  
 
Our previous studies showed that the CD spectra of apo NColE7 shifted slightly upon 
binding the Zn2+ ion, as a consequence of minor changes in the solution structure [73] and the 
addition of Zn2+ ions to N4-ZF-C105 AN resulted in a spectral shift, similar to that observed 
for NColE7 itself [77]. The above cataytic results using C45-ZF-N85 are in agreement with 
these observations. First the zinc binding to the AN lacking the metal ion in the active center 
increases its catalytic activity, while the metal ion binding to the catalytic histidine decreases 
the nuclease activity. At 1:1 protein-to-Zn2+ molar ratio, the catalytic center of C45-ZF-N85 is 
saturated with the Zn2+ then H545 may also be metallated on further addition of metal ion, 
preventing the generation of the OH− nucleophile by the sidechain of this histidine residue. The 
higher is the metal ion excess the higher is the probability of this type of coordination as shown 
previously [189]. 
The Zn2+ ion is not required for DNA binding, but it is essential for DNA hydrolysis in 
NColE7 [171]. During the catalytic reaction, the Zn2+ ion in the active center binds the oxygen 
donor atoms of the DNA scissile phosphodiester group. The positively charged amino acids at 
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the N-terminus are sterically close to the catalytic site. R447 is bridged with the Zn2+ ion by the 
scissile phosphodiester group [80]. The metal ion, having a free coordination site, has essential 
multiple roles in DNA cleavage since it stabilizes the active centre, polarizes the P–O bond for 
nucleophilic attack. In addition it is suggested to stabilize the phosphoanion transition state and 
the leaving sugar alcoholate group. The attacking nucleophilic OH– in NColE7 is supposed to 
be generated by the most conserved histidine residue of the HNH motif which does coordinate 
to the Zn2+ ion.  
In case of incomplete saturation of the zinc finger units by the metal ion, oxidation of 
the thiol groups into disulfide bridges may easily occur. This will most probably result in 
inactive protein. The cleavage experiment of the pGEX-6P-1-Z0 plasmid was performed by 
C45-ZF-N85 under reducing conditions, as well, to verify the integrity of the ANs. C45-ZF-
N85 was treated by 100 equivalents of tris(2-carboxyethyl)phosphine (TCEP)  as a reducing 
reagent. It was expected that by reducing the eventual disulfide bonds within the AN protein, 
lacking some of the zinc ions, its catalytic activity will increase. The catalytic activity of the 
TCEP treated-protein was monitored in the presence of varying Zn2+ ion equivalents (Figure 
5.36).  
 
 
Figure 5.36. Agarose gel electrophoresis images showing the cleavage of pGEX-6P-1-Z0 (12 
nM) by 200 nM C45-ZF-N85 protein and treated by 100 equivalents of TCEP in the presence 
of increasing amounts of Zn2+ ions. Each column in one experiment represents the catalytic 
activity after 1, 3, 24 h, from left to right. 
 
The untreated protein in the presence of 1 equivalent Zn2+ served as a positive control. 
The DNA cleavage was inhibited completely at 1:100:1 protein to TCEP to Zn2+ ratio. This 
may be due to the combined effect of the decrease of the zinc(II) amount available for the 
catalytic center: (i) the reduction of any disulfide bonds results in metal ion binding by the 
tiolate donors (ii) the TCEP excess can bind metal ion. The catalytic activity increased again 
by adding 2 and 3 equivalents Zn2+ ion to the reaction mixture. Although the catalytic activity 
was expected to increase more than the positive control upon increase of the active catalyst 
concentration by increasing the Zn2+ ion amounts, it did not happen within the conditions of the 
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present experiment series. This is most probably attributed to the possibility of the multiple 
metal ion binding modes in this complicated system. 
5.5.5. Double strand cleavage in short oligonucleotides 
 As mentioned above, we could not achieve double strand DNA cleavage by using the 
pGEX-6P-1-Z0 plasmid as  the substrate. Therefore, a short dsDNA (ZV, 37bp) was designed 
for the catalytic experiments to confirm the double-strand cleavage by C45-ZF-N85. The short 
DNA contains two ZF recognition sequences separated by the restriction site of VspI restriction 
enzyme (Figure 5.37 a). The recognition site of VspI was added to use this enzyme as a positive 
control for the double-strand DNA cleavage. Another 34 bp dsDNA (S0), which does not 
contain the recognition site of C45-ZF-N85 protein and the VspI restriction site was applied as 
a negative control. (Forward strand: 5’–ctagtttgctgaactggggtcacatagattaata-3’ and reverse 
strand: 3’-gatcaaacgacttgaccccagtgtatctaattat-5’). Both ZV and S0 dsDNAs were synthesized 
as complementary forward and reverse ssDNA strands and hybridized by PCR through 
increasing the temperature to 95 ºC and cooling to 4 ºC step by step.  
 
 
Figure 5.37. a, Illustration of ZV short oligonucleotide which consists of two 1MEY 
recognition sites (shown in blue and red) and separated by VspI restriction site (yellow 
highlighted) and the expected fragment products which result from the cleavage experiment. b, 
UREA-PAGE (15%) analysis of the cleavage reaction products of oligonucleotides by VspI 
and C45-ZF-N85. The reaction mixtures containing 1000 nM substrate, 400 nM protein, 400 
nM ZnSO4, 100 mM NaCl and 20 mM Tris pH 7.9 were incubated for up to 48 h at 37 ºC. The 
reaction was stopped by formamide and freezing at -20 °C. Mixture of ssDNAs with different 
nucleotides (nt) size (72, 34, 22, and 18) was used as a reference. The digestion reaction of ZV 
and S0 was performed also by VspI restriction endonuclease at 37 °C for two hours as a positive 
control. 
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The cleavage of S0 and ZV was monitored by urea PAGE gel, in which ZV was 
expected to appear as four single strand fragments upon the single strand cleavages on  both 
strands of the dsDNA. The resulting fragmentation pattern by VspI and C45-ZF-N85 is 
expected to be similar, as shown in Figure 5.37 b. After 24 h ZV DNA was cleaved but S0 
DNA was not affected by both the restriction endonuclease and the C45-ZF-N85 AN. This 
catalytic activity experiment proved that double strand cleavage may be obtained by C45-ZF-
N85 within a suitably designed cleavage sequence. The above results showed that activation of 
the C-terminal HNH nuclease motif was possible by fusion of the N85 N-terminal segment to 
the ZF in integrated ANs. Further improvement requires optimization of the molecular design. 
 
5.5.6. Mutation of the C45-ZF-N85 and C45-ZF nucleases for targeting ErbB1(EGFR) 
oncogene  
To prove the structural variability of the newly designed AN, we introduced changes in 
the zinc finger domain to target the EGFR gene at the same DNA sequence as it was selected 
for the CRISPR/Cas9 system designed in chapter 5.3. Each recognition site consists of three 
fingers. Mutations the DNA sequence were performed in a stepwise manner by a modified 
QuikChange PCR protocol using a different sets of primers for each zinc finger unit. The 
success of the mutations was confirmed by DNA sequencing. The initial check of the catalytic 
activity was carried out in transformed BL21 (DE3) cells, similarly as described in section 5.5.2.  
 
 
Figure 5.38. Agarose gel electrophoresis picture of the DNA preparations from BL21 (DE3) 
E. coli cells transformed by plasmids encoding for various C45-ZF*-N85 and C45-ZF* with 
mutated zinc fingers to target ErbB1. Plasmids encoding C45-ZF-N85 and C45-ZF were used 
as a positive control. Gene Ruler 1kb Plus DNA ladder served as the reference. Lane 5 most 
probably contains a wrong plasmid. 
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The available full size (C45-ZF*-N85) and truncated (C45-ZF*) protein versions were 
compared to each other in this experiment. The applied plasmids contain the gene of ANs with 
one, two or three modified zinc fingers for one of the two recognition sites (A and B) positioned 
oppositely within the DNA targeting region. The DNA was purified from the transformed 
bacterial cells and analysed by agarose gel electrophoresis (Figure 5.38). The results showed 
the nonspecific cleavage properties of the full size proteins against the plasmid DNA similarly 
to the prototype C45-ZF-N85. In contrary, the plasmids containing the genes of the truncated 
C45-ZF* proteins remained intact. These results suggest the robustness of the designed AN.  
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6. SUMMARY AND FUTURE OUTLOOK 
 
My PhD research work is a part of the research project conducted in the Bioinorganic 
Chemistry Research Group in the Chemistry Institute of University of Szeged, aiming to 
develop effective artificial nucleases as promising molecular tools for gene therapy. Such 
nucleases need to be safe in terms of avoiding off-target cleavages. Therefore, novel zinc finger 
ANs were designed based on the NColE7 nuclease domain. The HNH active center of NColE7 
enzyme functions under intramolecular allosteric activation, providing the basis for a new 
approach towards integrated artificial nucleases. In the resulting constructs the allosteric 
activation is expected to occur upon the specific DNA recognition by the zinc finger domain. 
The optimization of such regulated ANs can lead to gene editing enzymes applicable in parctice.  
Therefore, in my work I investigated the newly designed ANs to achieve deeper 
understanding about the mechanism of this new nuclease. This knowledge can be utilized 
further in the AN design to achieve better regulation and specificity. The robustness of the 
design is also verified by the variability of the zinc finger domain, to target various DNA 
sequences, beside the prototype model. I used CRISPR/Cas9 artificial nuclease for knocking 
out oncogenes in order to identify suitable target DNA sequences for artificial nucleases, which 
can be applied in gene therapy of cancer, and to compare them with the currently often used 
CRISPR/Cas9 artificial nucleases. I also developed a novel drug delivery system to increase 
the efficiency of the ANs. 
In the first part of my work, I designed a new DNA construct (pET-21a*-SRHS) for 
affinity purification strategy of proteins with a native sequence. This DNA construct allows for 
the removal of the affinity tag avoiding any remnant amino acid residues, while overcoming 
several disadvantages of the proteases: sensitivity, high price and extra amino acids remaining 
after the protease cleavage. Such DNA carrier can provide a feasible purification pathway for 
those proteins, where the sequence is precisely determined e.g. by the computer design. The 
synthesis of the ANs relies on precise reproduction of the designed sequence. The new DNA 
construct can be used with various tags at the C-terminus for affinity chromatographic 
applications.  
I observed that the C-terminal 6×His tag of the new construct causes an inhibitory effect 
by which the catalytic activity of the NColE7 or other metalloenzymes can be modulated in a 
multiple manner without changing the core enzyme sequence. In the light of this the genes of 
NColE7 protein and its R447G (KGNK) mutant were successfully cloned into a modified pET-
21a*-SRHS DNA vector fusing the 6×His affinity tag to the proteins upon expression. The 
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cloning into pET-21a would be otherwise not be possible in the absence of the gene of the Im7 
inhibitory protein. The solution secondary structure of KGNK 6×His protein was studied by 
CD technique and the CD spectrum evaluated by the BeStSel software revealed that its relative 
α-helical content is ~14%. This result suggested that the protein was obtained in its functionally 
folded form. ESI-MS was applied to validate the molecular mass and to monitor metal ion 
binding property of the KGNK-6×His protein. Accordingly, this protein was able to bind up to 
six Zn2+ ions under the measurement conditions. Based on ESI-MS measurements, the relative 
amounts of the complexes containing various numbers of metal ions were estimated and plotted 
versus the added Zn2+ equivalents. The catalytic activity experiments at increasing Zn2+ ion to 
protein concentration ratio revealed that the DNA cleavage ability of the 6×His tagged enzyme 
was first enhanced by an increase of the metal ion concentration, while high excess of Zn2+ ions 
caused a lower rate of the DNA cleavage. Based on the comparison of the MS and catalytic 
experiments I concluded that the initial inhibition by the 6×His tag was at least partially caused 
by its binding to the free coordination site of the Zn2+ ion in the active center. Saturation of the 
tag by metal ions leads to increase of the activity, as the original coordination sphere of the 
catalytic Zn2+ ion was restored. Upon further increase of Zn2+ amounts the catalytic histidine is 
also inhibited by the metal ion excess. Mutations within the C terminal tag revealed that the 
inhibitory effect of the 6 × His fusion tag on the nuclease activity is a complex process via both 
coordinative and non-specific steric interactions. 
New ZFNs were designed by Dr. Eszter Németh as CY-ZF-NX and CY-ZF in which the 
CY catalytic center and NX activator sequences of NColE7 were fused these to the opposite 
termini of a zinc finger protein, which is the DNA recognition domain. We found that among 
the various constructs with X+Y = 130, C45-ZF-N85 variant is under intramolecular allosteric 
regulation. C45-ZF-N85, C45-ZF, as well as W/A and R/G mutants of C45-ZF-N85 protein 
were successfully expressed and purified by cation exchange chromatography. The catalytic 
activity was also studied by using nonspecific and specific DNA (pGEX plasmid and Z0 
plasmid). Z0 plasmid contains the recognition site of the artificial nuclease and is cleaved into 
the open circular form by C45-ZF-N85. The truncated version C45-ZF, however, did not cleave 
the DNA. By this, we could prove that the catalytic domain cannot work in the absence of the 
activator and C45-ZF-N85 is a very promising artificial nuclease enzyme.  
The variability of the recognition sequence of the above ANs was also checked. For this, 
first the CRISPR/Cas9 system was used in my PhD study to detect which DNA target sequence 
could be suitable for the practical application of the new zinc finger nuclease. New guide RNA 
sequences were designed to target lung cancer through EGFR oncogene by CRISPR/Cas9 
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system. The new CRISPR/Cas9 plasmids were used for transfection of A549 lung cancer cells 
and mutation efficiencies around 7.5% were revealed after seven days incubation period by the 
sequencing of the target region of the genomic DNA. Further improvement of the gene editing 
efficiency is needed. The redesign of the zinc-finger part of the new ANs has been initiated 
through several steps of single finger mutations. Comparison of the full length and truncated 
versions proved the robustness of the AN design.  
A water-soluble cationic lipopolymer (WSLP) was synthesized as a novel drug delivery 
system as a candidate to improve the efficiency of the artificial nuclease action in cells. WSLP 
was prepared by the modification of high molecular weight branched poly(ethylenimine) (PEI) 
with cholesteryl chloroformate, then it was characterized and assessed for DNA loading and 
cellular membrane permeability. The cholesterylation was efficient, in average ~ 10% of the 
PEI nitrogens were reacted. This kind of modification of a cytotoxic high molecular weight PEI 
proved to be promising, since it retained the positive charges for strong interaction with DNA, 
while decreased the toxicity of the preparation. pEGFP-N3 and a CRISPR/Cas9 (pX458) carrier 
plasmid DNA both expressing the GFP fluorescent protein for detectability of transfection were 
efficiently condensed by the new water soluble lipopolymer. A549 and HeLa cells were 
efficiently transfected under the applied conditions. WSLP/pX458 complexes could achieve ~ 
8% mutation efficiency in A549 cancer cells at 10/1 N/P ratio. 
The results of my PhD work demonstrate how the specificity and effectivity of artificial 
metallonuleases can be improved by regulating the enzymatic function and by developing 
effective drug delivery system. In the future, we plan to better understand the gene editing of 
the artificial nucleases by using cell sorting technique to separate the transfected cells. In this 
way, the properties of the newly designed enzymes can be compared with others, e.g. with the 
CRISPR/Cas9 system. In my hope, the results of my PhD studies are expected to contribute to 
the development of better molecular tools towards cancer gene therapy. 
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10. APPENDIX 
 
A. 1. pET-21a plasmid 
Plasmid pET-21a was purchased from Novagen and used in our laboratory for DNA 
cloning and protein expression. It provides ampicillin resistance as a selectable marker in E. 
Coli and contains C-terminal His•Tag sequence for the purpose of protein purification. 
Schematic representation of plasmid pET-21a from Addgene was shown below.  
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A.2. pEGFP-N3 plasmid  
pEGFP-N3 plasmid from BD Bioscience Clontech was used as a reference for loading 
it into the WSLP, it provides kanamycin resistance as a selectable marker in E. Coli. It can be 
used simply to express EGFP in the mammalian cell lines of interest as a transfection marker. 
A map of pEGFP-N3 is shown below.  
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A.3. pX458 (pSpCas9(BB)-2A-GFP plasmid 
Plasmid pX458 (pSpCas9(BB)-2A-GFP from Addgene) was chosen for our study as it 
provides ampicillin resistance as a selectable marker in E. coli and offers green fluorescent 
protein (GFP) expression for tracking in mammalian cells. A map of pX458 is shown below. 
This plasmid encodes for the expression of a CRISPR single guide RNA (sgRNA), Cas 9 
protein and 2A-EGFP simultaneously. It contains U6 promoter which controls the transcription 
of the guide RNAs by RNA polymerase III in cells.  
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A.4. DNA sequence of Exon1 and Exon17 for the epidermal growth factor receptor 
(EGFR, ErbB1) oncogene (Homo sapiens transcript variant 1) 
The target genes selected to design the gRNA are included below. 
Exon 1 
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGC
CGAGGCGGCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGC
CACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGCGCACGG
CCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGAT
GCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGA
GTCGGGCTCTGGAGGAAAAGAAAG 
 
Exon 17 
GGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGAG
GCTGCTGCAGGAGAGGGAG 
 
A.5. Annealing of gRNA oligonucleotides: 
The forward and reverse gRNA sequences were annealed together by using the thermal 
cycler as follows (95C 2 min then decrease the temperature gradually to 25C with a gradient 
-1C / min; 70 cycles).  
Reaction mixture Volume 
Forward oligonucleotide (100 μM) 1 µl 
Reverse oligonucleotide (100 μM) 1 µl 
MilliQ H2O 8 µl 
Total 10 µl 
 
  
116 
 
A. 6. Genomic DNA extraction and sequencing 
The genomic DNA was extracted from the transfected cells to sequence the targeted 
DNA segments to check the EGFR oncogene knock-out efficiency of the applied CRISPR/Cas9 
systems. The primers used to amplify the targeted regions located on exon 17 in the PCR 
reaction are listed below. The PCR products were loaded to 1% agarose gel to check the primer 
specificity then the gel bands were sliced and the PCR products purified by GeneJET Gel 
Extraction Kit (Thermo Scientific). The purified PCR products were sequenced by Sanger 
sequencing using the forward primer of the primer set used for each reaction.  
 
Table A2 . Sequence of the primers used in the PCR  
Name Sequence (5’ – 3’) 
E17-FD GGAAACGTTGCCTTAGAAG 
E17-RD GCTTTGTGGACATTGAAGG 
 
A.7. RNA extraction and SYBR-based qRT-PCR analysis 
Total RNA was extracted from A549 cells after 72 h incubation by using RNeasy Plus 
Mini Kit (QIAGEN, GERMANY). One microgram of RNA was reverse transcribed to cDNA 
by using  RT Kit (Taqman Reverse Transcription Reagents, Applied biosystem). The reverse 
transcription parameters were as follows: 25°C for 10 minutes, 37°C for 30 minutes, 95°C for 
5 minutes and cooling to 4°C indefinitely. qRT-PCR was performed using Thermo 
Scientific™ PikoReal™ Real-Time PCR System with SYBR Green Supermix (Bio-Rad, USA).  
200ng and 200nM of the cDNA and primers respectively were used in the reaction mixture. 
The PCR conditions used,  95°C, 7 min, followed by 40 cycles of 95°C, 15sec,  58°C,1min, 
data acquisition and  20°C,10 sec. EGFR expression was analyzed compared to the control by 
using delta delta Ct method. The housekeeping gene GAPDH was used for normalizing gene 
expression. 
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A.8. Determination of the molecular weight of PEI 
The average molecular weight of PEI was not provided and therefore, we had to 
determine it. For the average molecular mass of PEI Mw ~ 139±1 kDa was obtained from DLS 
measurements.  
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A.9. Determination of critical micelle concentration 
WSLP is able to behave like a surfactant and forms micelles in aqueous solutions thanks 
to its amphiphilic chemical structure. For the determination of CMC, representing the 
concentration, above which the micelle formation occurs. The CMC of WSLP was determined 
by dye solubilization method using fluorescence spectroscopy (λex = 490 nm, λem = 540 nm), 
with the photos of samples in daylight and under UV-lamp. Fluorescent Eosin red indicator was 
used. The fluorescence of the dyes is rather sensitive to the chemical environment. The increase 
of the WSLP concentration caused a decrease of the Eosin fluorescence intensity. WSLP 
behaves as a quencher of the dye. Based on the measured data, it can be established that the 
polymer applied at higher concentration than CMC caused complete fluorescence quenching in 
contrast to the conventional monocationic surfactants, where the fluorescence of the dye starts 
to increase above of CMC. The rapid decrease in the fluorescence intensity indicates the 
development of micelles, while the intensity does not change further upon completion of this 
process. The CMC of 0.35 ± 0.03 mg/mL was obtained by this method for the WSLP.  
 
 
  
119 
 
A.10. Details of WSLP/pEGFP-N3 complex preparation 
From pEGFP-N3 plasmid (stock concentration = 493.9 ng μL–1) ~ 1 μg amount was 
used for each sample preparation. Fresh samples of WSLP/pDNA were prepared according to 
either mass or N/P ratio. 
(1) According to the mass ratio (the ratio between m(WSLP) and m(DNA) in μg): 
Components  2.5/1 ratio 5/1 ratio 10/1 ratio 20/1 ratio 
pEGFP-N3 (1 μg) 2 μl 2 μl 2 μl 2 μl 
WSLP (1.0 mg mL–1) 2.5 μl (2.5 μg) 5μl (5 μg) 10 μl (10 μg) 20μl (20 μg) 
Water 45.5 μl 43 μl 38 μl 28 μl 
Total Volume 50 μl 50 μl 50 μl 50 μl 
(2) According to WSLP–DNA N/P ratio: 
2.5/1:  76 ng/200 ng/well 
5/1:  152 ng/200 ng/well 
10/1: 304 ng/200 ng/well 
20/1: 608 ng/200 ng/well 
 
Components  2.5/1 
ratio 
5/1 ratio 10/1 ratio 20/1 ratio 
pEGFP-N3 (1 μg)  2 μl 2 μl 2 μl 2 μl 
WSLP (1.0 mg mL–1) 0.38 μl 
(0.38 μg) 
0.76 μl  
(0.76 μg) 
1.52μl  
(1.52 μg) 
3.04μl  
(3.04 μg) 
Water  47.62 μl 47.24μl 46.48μl 44.96 μl 
Total Volume 50 μl 50 μl 50 μl 50 μl 
 
The mixtures were incubated for 20 minutes at room temperature and then stored at 4 C. For 
MTT assays 10 μl per well of these samples were applied so that the final amount of the DNA 
was 200 ng per well. Preparation of 2.5/1 ratio was not applied for the MTT assay. 
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A.11. Microscopic detection of the WSLP/pEGFP-N3 complexes cytotoxicity 
The microscopic images (100× magnification) of the cells treated with WSLP/pEGFP-
N3 complexes after 24 hours of incubation show that the majority of the cells are destroyed by 
the excess of the WSLP. Cytotoxicity was reasonably low even at 10/1 N/P ratio for A549 cells, 
nevertheless it depended remarkably on the type of the applied cell. 
A 
 
 
B 
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A.12. In vitro transfection 
A549 cells were transfected with pX458 complexes with WSLP, PEI and Lipofectamine 
at various N/P ratios. The transfection efficiency of the starting HMW PEI, as well as the 
commercial standard transfection reagent LipofectamineTM 3000 (Thermo Fisher Scientific) 
was also checked by Flow cytometric analysis for comparison. The results demonstrated high 
transfection efficiency of highly cytotoxic PEI. The efficiency of the WSLP/pX458-E17-GGG 
at N/P 10/1 ratio was similar to Lipofectamine.  
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A.13. Confocal microscopic images of A549 cells transfected by WSLP/pEGFP-N3 complexes 
at 10/1 N/P ratio. PEI was used as a control transfection agent. For each triplicate image, from 
left to right: cell nuclei stained by Hoechst; eGFP signals; merged image. The scale bar 
represents 200 μm. 
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A.14. Assessment of WSLP/pX458-E17-GGG complexes activity by in vitro gene 
knockout assay 
CodonCode Aligner sequences of EGFR demonstrating pX458-E17-GGG activity after seven 
days transfection by WSLP. Top sequence represents control sequence without gene knock-out. 
Highlighted region shows the region complementary to CRISPR single guide RNA. Second 
and third sequencing show slight increase in background noise, implying low CRISPR 
efficiency resulted from WSLP pX458-E17-GGG 10/1 and 20/1 respectively. b, c, TIDE data 
shows the percentage probability of insertion or deletion mutations on test sequence which 
correlates to mutation efficiency in the case of WSLP/pX458-E17-GGG 10/1 and 20/1 
respectively. 
 
 
 
 
 
a
b
c
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